10-K 1 ctva-20231231.htm 10-K ctva-20231231
10-K10-KFALSEFALSEDecember 31, 2023December 31, 202300017556720000030554December 31December 3120232023FYFYYesYesNoNoYesYesYesYesLarge Accelerated FilerNon-accelerated FilerFalseFalseFalseFalseFalseFalsefalsefalse0.010.011,666,667,0001,666,667,000701,260,000713,419,0000.580.540.52http://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2023#PropertyPlantAndEquipmentNethttp://fasb.org/us-gaap/2023#DebtCurrenthttp://fasb.org/us-gaap/2023#DebtCurrenthttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#LongTermDebtAndCapitalLeaseObligationshttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#OtherAssetsNoncurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2023#AccountsPayableCurrent120120102102http://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#OtherAssetsCurrenthttp://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2023#CostOfGoodsAndServicesSold0.300.301,800,000,0001,800,000,00020020023,000,00023,000,0001,673,0001,673,00012012023,000,00023,000,000700,000700,0001021024.504.504.503.503.503.5000017556722023-01-012023-12-310001755672dei:OtherAddressMember2023-01-012023-12-310001755672ctva:EIDPMember2023-01-012023-12-310001755672dei:OtherAddressMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:CommonStockMember2023-01-012023-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDPMember2023-01-012023-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDPMember2023-01-012023-12-3100017556722023-06-30iso4217:USD00017556722024-02-01xbrli:sharesiso4217:USDxbrli:shares0001755672ctva:EIDPMember2024-02-010001755672us-gaap:OtherPensionPlansDefinedBenefitMembersrt:ScenarioForecastMember2024-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMembersrt:ScenarioForecastMember2024-12-310001755672us-gaap:AllowanceForCreditLossMember2022-12-310001755672us-gaap:AllowanceForCreditLossMember2021-12-310001755672us-gaap:AllowanceForCreditLossMember2020-12-310001755672us-gaap:AllowanceForCreditLossMember2023-01-012023-12-310001755672us-gaap:AllowanceForCreditLossMember2022-01-012022-12-310001755672us-gaap:AllowanceForCreditLossMember2021-01-012021-12-310001755672us-gaap:AllowanceForCreditLossMember2023-12-310001755672us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-12-310001755672us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-12-310001755672us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2020-12-310001755672us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-01-012023-12-310001755672us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2022-01-012022-12-310001755672us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2021-01-012021-12-310001755672us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember2023-12-3100017556722022-01-012022-12-3100017556722021-01-012021-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-12-3100017556722023-12-3100017556722022-12-3100017556722021-12-3100017556722020-12-310001755672us-gaap:CommonStockMember2020-12-310001755672us-gaap:AdditionalPaidInCapitalMember2020-12-310001755672us-gaap:RetainedEarningsMember2020-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001755672us-gaap:NoncontrollingInterestMember2020-12-310001755672us-gaap:RetainedEarningsMember2021-01-012021-12-310001755672us-gaap:NoncontrollingInterestMember2021-01-012021-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-12-310001755672us-gaap:AdditionalPaidInCapitalMember2021-01-012021-12-310001755672us-gaap:CommonStockMember2021-12-310001755672us-gaap:AdditionalPaidInCapitalMember2021-12-310001755672us-gaap:RetainedEarningsMember2021-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001755672us-gaap:NoncontrollingInterestMember2021-12-310001755672us-gaap:RetainedEarningsMember2022-01-012022-12-310001755672us-gaap:NoncontrollingInterestMember2022-01-012022-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-12-310001755672us-gaap:AdditionalPaidInCapitalMember2022-01-012022-12-310001755672us-gaap:CommonStockMember2022-12-310001755672us-gaap:AdditionalPaidInCapitalMember2022-12-310001755672us-gaap:RetainedEarningsMember2022-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310001755672us-gaap:NoncontrollingInterestMember2022-12-310001755672us-gaap:RetainedEarningsMember2023-01-012023-12-310001755672us-gaap:NoncontrollingInterestMember2023-01-012023-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-12-310001755672us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001755672us-gaap:CommonStockMember2023-12-310001755672us-gaap:AdditionalPaidInCapitalMember2023-12-310001755672us-gaap:RetainedEarningsMember2023-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310001755672us-gaap:NoncontrollingInterestMember2023-12-310001755672ctva:CortevaMember2023-01-012023-12-31xbrli:pure0001755672ctva:SpecialtyProductsDisposalMember2023-01-012023-12-310001755672srt:MinimumMember2023-12-310001755672srt:MaximumMember2023-12-310001755672us-gaap:OtherCurrentAssetsMember2023-12-310001755672us-gaap:OtherAssetsMember2023-12-310001755672ctva:StollerMember2023-01-012023-12-310001755672ctva:SymborgMember2023-01-012023-12-310001755672ctva:StollerMember2023-12-310001755672ctva:SymborgMember2023-12-310001755672ctva:StollerMemberus-gaap:CustomerRelatedIntangibleAssetsMember2023-12-310001755672ctva:StollerMemberus-gaap:CustomerRelatedIntangibleAssetsMember2023-01-012023-12-310001755672ctva:StollerMemberus-gaap:DevelopedTechnologyRightsMember2023-12-310001755672ctva:StollerMemberus-gaap:DevelopedTechnologyRightsMember2023-01-012023-12-310001755672us-gaap:DevelopedTechnologyRightsMemberctva:SymborgMember2023-12-310001755672us-gaap:DevelopedTechnologyRightsMemberctva:SymborgMember2023-01-012023-12-310001755672ctva:StollerMemberus-gaap:TrademarksAndTradeNamesMember2023-12-310001755672ctva:StollerMemberus-gaap:TrademarksAndTradeNamesMember2023-01-012023-12-310001755672ctva:SymborgMemberus-gaap:TrademarksAndTradeNamesMember2023-12-310001755672ctva:SymborgMemberus-gaap:TrademarksAndTradeNamesMember2023-01-012023-12-310001755672us-gaap:InProcessResearchAndDevelopmentMemberctva:SymborgMember2023-12-310001755672us-gaap:OtherNoncurrentLiabilitiesMember2023-12-310001755672us-gaap:OtherNoncurrentLiabilitiesMember2022-12-310001755672ctva:CornMemberctva:SeedMember2023-01-012023-12-310001755672ctva:CornMemberctva:SeedMember2022-01-012022-12-310001755672ctva:CornMemberctva:SeedMember2021-01-012021-12-310001755672ctva:SeedMemberctva:SoybeanMember2023-01-012023-12-310001755672ctva:SeedMemberctva:SoybeanMember2022-01-012022-12-310001755672ctva:SeedMemberctva:SoybeanMember2021-01-012021-12-310001755672ctva:OtheroilseedsMemberctva:SeedMember2023-01-012023-12-310001755672ctva:OtheroilseedsMemberctva:SeedMember2022-01-012022-12-310001755672ctva:OtheroilseedsMemberctva:SeedMember2021-01-012021-12-310001755672ctva:OtherMemberctva:SeedMember2023-01-012023-12-310001755672ctva:OtherMemberctva:SeedMember2022-01-012022-12-310001755672ctva:OtherMemberctva:SeedMember2021-01-012021-12-310001755672ctva:SeedMember2023-01-012023-12-310001755672ctva:SeedMember2022-01-012022-12-310001755672ctva:SeedMember2021-01-012021-12-310001755672ctva:CropProtectionMemberctva:HerbicidesMember2023-01-012023-12-310001755672ctva:CropProtectionMemberctva:HerbicidesMember2022-01-012022-12-310001755672ctva:CropProtectionMemberctva:HerbicidesMember2021-01-012021-12-310001755672ctva:InsecticidesMemberctva:CropProtectionMember2023-01-012023-12-310001755672ctva:InsecticidesMemberctva:CropProtectionMember2022-01-012022-12-310001755672ctva:InsecticidesMemberctva:CropProtectionMember2021-01-012021-12-310001755672ctva:FungicidesMemberctva:CropProtectionMember2023-01-012023-12-310001755672ctva:FungicidesMemberctva:CropProtectionMember2022-01-012022-12-310001755672ctva:FungicidesMemberctva:CropProtectionMember2021-01-012021-12-310001755672ctva:OtherMemberctva:CropProtectionMember2023-01-012023-12-310001755672ctva:OtherMemberctva:CropProtectionMember2022-01-012022-12-310001755672ctva:OtherMemberctva:CropProtectionMember2021-01-012021-12-310001755672ctva:CropProtectionMember2023-01-012023-12-310001755672ctva:CropProtectionMember2022-01-012022-12-310001755672ctva:CropProtectionMember2021-01-012021-12-310001755672ctva:GeographyMember2023-01-012023-12-310001755672ctva:SeedMembersrt:NorthAmericaMember2023-01-012023-12-310001755672ctva:SeedMembersrt:NorthAmericaMember2022-01-012022-12-310001755672ctva:SeedMembersrt:NorthAmericaMember2021-01-012021-12-310001755672us-gaap:EMEAMemberctva:SeedMember2023-01-012023-12-310001755672us-gaap:EMEAMemberctva:SeedMember2022-01-012022-12-310001755672us-gaap:EMEAMemberctva:SeedMember2021-01-012021-12-310001755672srt:LatinAmericaMemberctva:SeedMember2023-01-012023-12-310001755672srt:LatinAmericaMemberctva:SeedMember2022-01-012022-12-310001755672srt:LatinAmericaMemberctva:SeedMember2021-01-012021-12-310001755672ctva:SeedMembersrt:AsiaPacificMember2023-01-012023-12-310001755672ctva:SeedMembersrt:AsiaPacificMember2022-01-012022-12-310001755672ctva:SeedMembersrt:AsiaPacificMember2021-01-012021-12-310001755672ctva:CropProtectionMembersrt:NorthAmericaMember2023-01-012023-12-310001755672ctva:CropProtectionMembersrt:NorthAmericaMember2022-01-012022-12-310001755672ctva:CropProtectionMembersrt:NorthAmericaMember2021-01-012021-12-310001755672us-gaap:EMEAMemberctva:CropProtectionMember2023-01-012023-12-310001755672us-gaap:EMEAMemberctva:CropProtectionMember2022-01-012022-12-310001755672us-gaap:EMEAMemberctva:CropProtectionMember2021-01-012021-12-310001755672srt:LatinAmericaMemberctva:CropProtectionMember2023-01-012023-12-310001755672srt:LatinAmericaMemberctva:CropProtectionMember2022-01-012022-12-310001755672srt:LatinAmericaMemberctva:CropProtectionMember2021-01-012021-12-310001755672ctva:CropProtectionMembersrt:AsiaPacificMember2023-01-012023-12-310001755672ctva:CropProtectionMembersrt:AsiaPacificMember2022-01-012022-12-310001755672ctva:CropProtectionMembersrt:AsiaPacificMember2021-01-012021-12-310001755672srt:MinimumMemberctva:CropProtectionStrategyOperationsProgramMember2023-12-310001755672ctva:CropProtectionStrategyOperationsProgramMembersrt:MaximumMember2023-12-310001755672srt:MinimumMemberctva:CropProtectionStrategyOperationsProgramMemberus-gaap:EmployeeSeveranceMember2023-12-310001755672ctva:CropProtectionStrategyOperationsProgramMemberus-gaap:EmployeeSeveranceMembersrt:MaximumMember2023-12-310001755672srt:MinimumMemberctva:AssetRelatedChargesMemberctva:CropProtectionStrategyOperationsProgramMember2023-12-310001755672ctva:AssetRelatedChargesMemberctva:CropProtectionStrategyOperationsProgramMembersrt:MaximumMember2023-12-310001755672us-gaap:ContractTerminationMembersrt:MinimumMemberctva:CropProtectionStrategyOperationsProgramMember2023-12-310001755672us-gaap:ContractTerminationMemberctva:CropProtectionStrategyOperationsProgramMembersrt:MaximumMember2023-12-310001755672ctva:CropProtectionStrategyOperationsProgramMember2023-01-012023-12-310001755672ctva:LeaseAssetMemberctva:CropProtectionStrategyOperationsProgramMember2023-01-012023-12-310001755672ctva:CropProtectionStrategyOperationsProgramMemberus-gaap:PropertyPlantAndEquipmentMember2023-01-012023-12-310001755672ctva:AssetRelatedChargesMemberctva:CropProtectionStrategyOperationsProgramMember2023-01-012023-12-310001755672us-gaap:ContractTerminationMemberctva:CropProtectionStrategyOperationsProgramMember2023-01-012023-12-310001755672ctva:AssetRelatedChargesMemberctva:CropProtectionStrategyOperationsProgramMember2022-12-310001755672us-gaap:ContractTerminationMemberctva:CropProtectionStrategyOperationsProgramMember2022-12-310001755672ctva:CropProtectionStrategyOperationsProgramMember2022-12-310001755672ctva:AssetRelatedChargesMemberctva:CropProtectionStrategyOperationsProgramMember2023-12-310001755672us-gaap:ContractTerminationMemberctva:CropProtectionStrategyOperationsProgramMember2023-12-310001755672ctva:CropProtectionStrategyOperationsProgramMember2023-12-310001755672ctva:A2022RestructuringActionsMember2023-12-310001755672ctva:A2022RestructuringActionsMemberus-gaap:EmployeeSeveranceMember2023-12-310001755672ctva:A2022RestructuringActionsMemberctva:AssetRelatedChargesMember2023-12-310001755672us-gaap:ContractTerminationMemberctva:A2022RestructuringActionsMember2023-12-310001755672ctva:A2022RestructuringActionsMemberus-gaap:OtherRestructuringMember2023-12-310001755672ctva:A2022RestructuringActionsMembersrt:MaximumMember2023-12-310001755672ctva:A2022RestructuringActionsRussiaExitMember2023-12-310001755672ctva:A2022RestructuringActionsRussiaExitMemberus-gaap:EmployeeSeveranceMember2023-12-310001755672ctva:A2022RestructuringActionsRussiaExitMemberctva:AssetRelatedChargesMember2023-12-310001755672us-gaap:ContractTerminationMemberctva:A2022RestructuringActionsRussiaExitMember2023-12-310001755672ctva:InventoryWriteOffsMemberctva:A2022RestructuringActionsRussiaExitMemberus-gaap:CostOfSalesMember2023-12-310001755672ctva:A2022RestructuringActionsRussiaExitMemberus-gaap:SettlementWithTaxingAuthorityMemberus-gaap:OtherIncomeMember2023-12-310001755672ctva:A2022RestructuringActionsMember2023-01-012023-12-310001755672ctva:A2022RestructuringActionsMemberctva:SeedMember2023-01-012023-12-310001755672ctva:A2022RestructuringActionsMemberctva:SeedMember2022-01-012022-12-310001755672ctva:CropProtectionMemberctva:A2022RestructuringActionsMember2023-01-012023-12-310001755672ctva:CropProtectionMemberctva:A2022RestructuringActionsMember2022-01-012022-12-310001755672ctva:A2022RestructuringActionsMemberus-gaap:CorporateMember2023-01-012023-12-310001755672ctva:A2022RestructuringActionsMemberus-gaap:CorporateMember2022-01-012022-12-310001755672ctva:A2022RestructuringActionsMember2022-01-012022-12-310001755672ctva:A2022RestructuringActionsMemberus-gaap:EmployeeSeveranceMember2023-01-012023-12-310001755672ctva:A2022RestructuringActionsMemberus-gaap:EmployeeSeveranceMember2022-01-012022-12-310001755672ctva:A2022RestructuringActionsMemberctva:AssetRelatedChargesMember2023-01-012023-12-310001755672ctva:A2022RestructuringActionsMemberctva:AssetRelatedChargesMember2022-01-012022-12-310001755672us-gaap:ContractTerminationMemberctva:A2022RestructuringActionsMember2023-01-012023-12-310001755672us-gaap:ContractTerminationMemberctva:A2022RestructuringActionsMember2022-01-012022-12-310001755672ctva:A2022RestructuringActionsMemberus-gaap:EmployeeSeveranceMember2022-12-310001755672ctva:A2022RestructuringActionsMemberctva:AssetRelatedChargesMember2022-12-310001755672us-gaap:ContractTerminationMemberctva:A2022RestructuringActionsMember2022-12-310001755672ctva:A2022RestructuringActionsMember2022-12-310001755672ctva:A2021RestructuringActionsMember2023-12-310001755672us-gaap:EmployeeSeveranceMemberctva:A2021RestructuringActionsMember2023-12-310001755672ctva:AssetRelatedChargesMemberctva:A2021RestructuringActionsMember2023-12-310001755672us-gaap:AssetRetirementObligationCostsMemberctva:A2021RestructuringActionsMember2023-12-310001755672us-gaap:ContractTerminationMemberctva:A2021RestructuringActionsMember2023-12-310001755672ctva:A2021RestructuringActionsMember2023-01-012023-12-310001755672ctva:SeedMemberctva:A2021RestructuringActionsMember2023-01-012023-12-310001755672ctva:SeedMemberctva:A2021RestructuringActionsMember2022-01-012022-12-310001755672ctva:SeedMemberctva:A2021RestructuringActionsMember2021-01-012021-12-310001755672ctva:CropProtectionMemberctva:A2021RestructuringActionsMember2023-01-012023-12-310001755672ctva:CropProtectionMemberctva:A2021RestructuringActionsMember2022-01-012022-12-310001755672ctva:CropProtectionMemberctva:A2021RestructuringActionsMember2021-01-012021-12-310001755672us-gaap:CorporateMemberctva:A2021RestructuringActionsMember2023-01-012023-12-310001755672us-gaap:CorporateMemberctva:A2021RestructuringActionsMember2022-01-012022-12-310001755672us-gaap:CorporateMemberctva:A2021RestructuringActionsMember2021-01-012021-12-310001755672ctva:A2021RestructuringActionsMember2022-01-012022-12-310001755672ctva:A2021RestructuringActionsMember2021-01-012021-12-310001755672us-gaap:EmployeeSeveranceMemberctva:A2021RestructuringActionsMember2023-01-012023-12-310001755672us-gaap:EmployeeSeveranceMemberctva:A2021RestructuringActionsMember2022-01-012022-12-310001755672us-gaap:EmployeeSeveranceMemberctva:A2021RestructuringActionsMember2021-01-012021-12-310001755672ctva:AssetRelatedChargesMemberctva:A2021RestructuringActionsMember2023-01-012023-12-310001755672ctva:AssetRelatedChargesMemberctva:A2021RestructuringActionsMember2022-01-012022-12-310001755672ctva:AssetRelatedChargesMemberctva:A2021RestructuringActionsMember2021-01-012021-12-310001755672us-gaap:ContractTerminationMemberctva:A2021RestructuringActionsMember2023-01-012023-12-310001755672us-gaap:ContractTerminationMemberctva:A2021RestructuringActionsMember2022-01-012022-12-310001755672us-gaap:ContractTerminationMemberctva:A2021RestructuringActionsMember2021-01-012021-12-310001755672ctva:OtherAssetRelatedMember2023-01-012023-12-310001755672ctva:OtherAssetRelatedMember2022-01-012022-12-310001755672ctva:OtherAssetRelatedMember2021-01-012021-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:CropProtectionMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:CropProtectionMember2021-01-012021-12-310001755672ctva:HedgingProgramMemberctva:ArgentinepesodevaluationMember2023-01-012023-12-310001755672ctva:HedgingProgramMemberctva:ArgentinepesodevaluationMember2022-01-012022-12-310001755672ctva:HedgingProgramMemberctva:ArgentinepesodevaluationMember2021-01-012021-12-310001755672srt:SubsidiariesMember2023-01-012023-12-310001755672srt:SubsidiariesMember2022-01-012022-12-310001755672srt:SubsidiariesMember2021-01-012021-12-310001755672ctva:HedgingProgramMember2023-01-012023-12-310001755672ctva:HedgingProgramMember2022-01-012022-12-310001755672ctva:HedgingProgramMember2021-01-012021-12-310001755672ctva:SeedGrowerCompensationMember2023-12-310001755672ctva:SeedGrowerCompensationMember2022-12-310001755672us-gaap:SegmentContinuingOperationsMember2023-01-012023-12-310001755672us-gaap:SegmentContinuingOperationsMember2022-01-012022-12-310001755672us-gaap:SegmentContinuingOperationsMember2021-01-012021-12-310001755672ctva:ExpiringwithinFiveYearsMember2023-12-310001755672ctva:ExpiringwithinFiveYearsMember2022-12-310001755672ctva:ExpiringAfterFiveYearsOrHavingIndefiniteExpirationMember2023-12-310001755672ctva:ExpiringAfterFiveYearsOrHavingIndefiniteExpirationMember2022-12-310001755672us-gaap:OtherAffiliatesMember2023-12-310001755672us-gaap:OtherAffiliatesMember2022-12-310001755672ctva:FactoringAgreementMember2023-01-012023-12-310001755672ctva:FactoringAgreementMember2022-01-012022-12-310001755672ctva:FactoringAgreementMember2021-01-012021-12-310001755672ctva:FactoringAgreementMember2023-12-310001755672ctva:FactoringAgreementMember2022-12-310001755672us-gaap:LandAndLandImprovementsMember2023-12-310001755672us-gaap:LandAndLandImprovementsMember2022-12-310001755672us-gaap:BuildingMember2023-12-310001755672us-gaap:BuildingMember2022-12-310001755672us-gaap:MachineryAndEquipmentMember2023-12-310001755672us-gaap:MachineryAndEquipmentMember2022-12-310001755672us-gaap:ConstructionInProgressMember2023-12-310001755672us-gaap:ConstructionInProgressMember2022-12-310001755672srt:MinimumMemberus-gaap:BuildingMember2023-12-310001755672srt:MaximumMemberus-gaap:BuildingMember2023-12-310001755672us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MinimumMember2023-12-310001755672us-gaap:ComputerSoftwareIntangibleAssetMembersrt:MaximumMember2023-12-310001755672ctva:CropProtectionMember2021-12-310001755672ctva:SeedMember2021-12-310001755672ctva:CropProtectionMember2022-12-310001755672ctva:SeedMember2022-12-310001755672ctva:CropProtectionMember2023-12-310001755672ctva:SeedMember2023-12-310001755672ctva:GermplasmMember2023-12-310001755672ctva:GermplasmMember2022-12-310001755672us-gaap:CustomerRelatedIntangibleAssetsMember2023-12-310001755672us-gaap:CustomerRelatedIntangibleAssetsMember2022-12-310001755672ctva:DevelopedTechnologyMember2023-12-310001755672ctva:DevelopedTechnologyMember2022-12-310001755672us-gaap:TrademarksAndTradeNamesMember2023-12-310001755672us-gaap:TrademarksAndTradeNamesMember2022-12-310001755672us-gaap:OtherIntangibleAssetsMember2023-12-310001755672us-gaap:OtherIntangibleAssetsMember2022-12-310001755672us-gaap:InProcessResearchAndDevelopmentMember2023-12-310001755672us-gaap:InProcessResearchAndDevelopmentMember2022-12-310001755672srt:MinimumMember2023-01-012023-12-310001755672srt:MaximumMember2023-01-012023-12-310001755672ctva:OtherloansvariouscurrenciesMember2023-12-310001755672ctva:OtherloansvariouscurrenciesMember2022-12-310001755672ctva:NotesMaturing2025Domainus-gaap:LoansPayableMember2023-12-310001755672ctva:NotesMaturing2025Domainus-gaap:LoansPayableMember2022-12-310001755672ctva:NotesMaturing2026Domainus-gaap:LoansPayableMember2023-12-310001755672ctva:NotesMaturing2026Domainus-gaap:LoansPayableMember2022-12-310001755672us-gaap:LoansPayableMemberctva:NotesMaturing2030Domain2023-12-310001755672us-gaap:LoansPayableMemberctva:NotesMaturing2030Domain2022-12-310001755672us-gaap:LoansPayableMemberctva:NotesMaturing2033Domain2023-12-310001755672us-gaap:LoansPayableMemberctva:NotesMaturing2033Domain2022-12-310001755672us-gaap:LoansPayableMemberctva:ForeignCurrencyLoansMember2023-12-310001755672us-gaap:LoansPayableMemberctva:ForeignCurrencyLoansMember2022-12-310001755672us-gaap:MediumTermNotesMember2023-12-310001755672us-gaap:MediumTermNotesMember2022-12-310001755672ctva:NotesMaturing2024Domain2023-01-012023-12-310001755672ctva:NotesMaturing2025Domain2023-01-012023-12-310001755672ctva:NotesMaturing2026Domain2023-01-012023-12-310001755672us-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:FairValueInputsLevel2Member2022-12-310001755672ctva:ForeignCurrencyLoansMember2023-12-310001755672ctva:RevolvingCreditFacilitiesDue2027Member2023-12-310001755672ctva:RevolvingCreditFacilitiesDue2025Member2023-12-310001755672ctva:A364DayRevolvingCreditFacilityMember2023-12-310001755672ctva:RevolvingCreditFacilitiesDue2027Member2022-05-030001755672ctva:RevolvingCreditFacilitiesDue2027Member2022-05-032027-05-030001755672ctva:RevolvingCreditFacilitiesDue2025Member2022-05-030001755672ctva:RevolvingCreditFacilitiesDue2025Member2022-05-032025-05-030001755672us-gaap:RevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2022-05-032027-05-030001755672us-gaap:RevolvingCreditFacilityMember2023-12-310001755672ctva:A364DayRevolvingCreditFacilityMember2023-01-272024-02-260001755672ctva:A364DayRevolvingCreditFacilitiesDue2024Member2023-01-270001755672ctva:A364DayRevolvingCreditFacilityMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember2023-01-272024-02-260001755672ctva:A364DayRevolvingCreditFacilitiesDue2024Member2023-02-010001755672ctva:A364DayRevolvingCreditFacilitiesDue2024Member2023-05-010001755672ctva:A364DayRevolvingCreditFacilitiesDue2024Member2023-07-010001755672ctva:A364DayRevolvingCreditFacilitiesDue2024Member2023-08-010001755672ctva:LessThanOneYear2023-12-310001755672ctva:FactoringAgreementMember2023-12-310001755672ctva:FactoringAgreementMember2022-12-310001755672ctva:AgreementsWithLendersToProvideFinancingForSelectCustomersMember2023-12-310001755672ctva:AgreementsWithLendersToProvideFinancingForSelectCustomersMember2022-12-310001755672ctva:PFOAMattersMultiDistrictLitigationMember2018-12-31ctva:lawsuits0001755672ctva:PFASMembersrt:MaximumMember2023-01-012023-12-310001755672ctva:PFASMembersrt:MaximumMember2023-12-310001755672ctva:DuPontDeNemoursAndCortevaMemberctva:PFASMember2023-12-310001755672ctva:DuPontDeNemoursAndCortevaMemberctva:PFASMembersrt:MaximumMember2023-12-310001755672ctva:DuPontdeNemoursMember2023-12-310001755672ctva:CortevaMember2023-12-310001755672ctva:PFASMembersrt:MaximumMemberctva:CortevaMember2023-12-310001755672ctva:PFASMemberctva:ChemoursMember2025-09-300001755672ctva:DuPontDeNemoursAndCortevaMemberctva:PFASMember2025-09-300001755672ctva:PFASMemberctva:ChemoursMembersrt:ScenarioForecastMember2031-09-300001755672ctva:DuPontDeNemoursAndCortevaMemberctva:PFASMembersrt:ScenarioForecastMember2031-09-300001755672ctva:PFASMemberctva:ChemoursMembersrt:MaximumMembersrt:ScenarioForecastMember2031-09-300001755672ctva:DuPontDeNemoursAndCortevaMemberctva:PFASMembersrt:MaximumMembersrt:ScenarioForecastMemberctva:CortevaMember2031-09-300001755672ctva:PFASMembersrt:ScenarioForecastMember2028-12-310001755672ctva:PFASMemberctva:ChemoursMember2023-12-310001755672ctva:DuPontdeNemoursMemberctva:PFASMemberctva:CortevaMember2023-12-310001755672ctva:PFASMember2023-12-310001755672ctva:PFASMembersrt:MinimumMember2023-12-310001755672ctva:Once300millionthresholdismetMemberctva:PFASMembersrt:MinimumMember2023-12-310001755672ctva:AccountsandNotesReceivableMember2023-12-310001755672ctva:AccountsandNotesReceivableMember2022-12-310001755672us-gaap:OtherAssetsMember2022-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMember2023-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMember2022-12-310001755672ctva:PFASMember2023-01-012023-12-310001755672ctva:PFASMember2022-01-012022-12-310001755672ctva:OtherDiscontinuedOrDivestedBusinessObligationsMember2022-01-012022-12-310001755672ctva:PFOAMattersDrinkingWaterActionsMember2004-01-012004-12-310001755672ctva:PFOAMattersDrinkingWaterActionsMember2012-01-010001755672ctva:PFOAMattersDrinkingWaterActionsMember2004-12-310001755672ctva:PFOAMattersDrinkingWaterActionsMember2012-01-012020-12-310001755672ctva:PFOAMattersDrinkingWaterActionsMember2023-12-310001755672ctva:PFOAMattersMultiDistrictLitigationMember2023-12-310001755672ctva:PFOAMattersMultiDistrictLitigationMember2017-04-012017-06-300001755672ctva:PostMDLSettlementPFOAPersonalInjuryClaimsDomainctva:CompensatoryDamagesMember2023-01-012023-12-310001755672ctva:PostMDLSettlementPFOAPersonalInjuryClaimsDomainctva:LossOfConsortiumMember2023-01-012023-12-310001755672ctva:PostMDLSettlementPFOAPersonalInjuryClaimsDomainctva:LossOfConsortiumMembersrt:MaximumMember2023-01-012023-12-310001755672ctva:PostMDLSettlementPFOAPersonalInjuryClaimsDomainctva:CompensatoryDamagesMemberctva:EIDPMember2023-01-012023-12-310001755672ctva:PFOAMattersDrinkingWaterActionsMemberus-gaap:SettledLitigationMemberctva:MDLSettlementMember2023-12-310001755672ctva:MDLSettlementMember2023-01-012023-12-310001755672ctva:ChemoursMemberctva:MDLSettlementMember2023-01-012023-12-310001755672ctva:DuPontDeNemoursAndCortevaMemberctva:MDLSettlementMember2023-01-012023-12-310001755672ctva:MDLSettlementMemberctva:CortevaMember2023-01-012023-12-310001755672ctva:FirefightingFoamMember2023-12-310001755672ctva:FirefightingFoamMemberctva:PersonalinjurycasesMember2023-12-310001755672ctva:NationwideWaterDistrictSettlementMemberctva:FirefightingFoamMember2023-12-310001755672ctva:NationwideWaterDistrictSettlementMember2023-12-310001755672ctva:NaturalResourcesDamagesMemberstpr:NJ2023-12-310001755672ctva:PFASMemberstpr:NJ2023-12-310001755672ctva:PFASMemberctva:NEWJERSEYANDNEWYORKMember2023-12-310001755672stpr:OHctva:NaturalResourcesDamagesMember2023-12-310001755672stpr:OHctva:NaturalResourcesDamagesMember2023-01-012023-12-310001755672ctva:PFOAMattersDrinkingWaterActionsMemberstpr:NY2023-12-310001755672ctva:NaturalResourcesDamagesMemberstpr:DE2023-12-310001755672ctva:NaturalResourcesDamagesMemberstpr:DE2023-01-012023-12-310001755672ctva:PFOAMattersDrinkingWaterActionsMembercountry:NL2022-12-310001755672stpr:NCctva:PFOAMattersDrinkingWaterActionsMember2023-01-012023-12-310001755672ctva:ChemoursrelatedobligationsubjecttoindemnificationMember2023-12-310001755672us-gaap:SegmentDiscontinuedOperationsMember2023-12-310001755672ctva:OtherDiscontinuedOrDivestedBusinessObligationsMember2023-12-310001755672ctva:EnvironmentalremediationliabilitiesprimarilyrelatedtoDuPontsubjecttoindemnityfromDuPontMember2023-12-310001755672ctva:NotsubjecttoindemnificationMember2023-12-310001755672ctva:IndemnificationLiabilitiesRelatedToTheMOUMember2023-12-310001755672ctva:DuPontdeNemoursMemberctva:DuPontdeNemoursMember2023-12-310001755672ctva:SuperfundSitesMemberctva:ChemoursMemberus-gaap:IndemnificationGuaranteeMember2023-12-310001755672ctva:NonPFASMember2022-01-280001755672ctva:A2022ShareRepurchaseProgramMember2022-09-130001755672ctva:CortevaMember2019-06-030001755672ctva:A2022ShareRepurchaseProgramMember2022-09-132023-12-310001755672ctva:A2021ShareRepurchaseProgramMember2021-08-050001755672ctva:A2021ShareRepurchaseProgramMember2023-01-012023-12-310001755672ctva:A2021ShareRepurchaseProgramMember2022-01-012022-12-310001755672ctva:A2021ShareRepurchaseProgramMember2021-01-012021-12-310001755672ctva:A2019ShareRepurchasePlanMember2019-06-260001755672ctva:CortevaMember2019-06-260001755672ctva:A2019ShareRepurchasePlanMember2019-01-012021-12-310001755672ctva:CortevaMemberctva:EIDMember2023-01-012023-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDMember2023-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDMember2023-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2020-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2020-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2020-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2020-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-01-012021-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-01-012021-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2021-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-01-012022-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-12-310001755672us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310001755672us-gaap:AccumulatedNetGainLossFromDesignatedOrQualifyingCashFlowHedgesMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001755672us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310001755672ctva:AccumulatedDefinedBenefitPlansAdjustmentSettlementGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001755672ctva:AccumulatedDefinedBenefitPlansAdjustmentSettlementGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001755672ctva:AccumulatedDefinedBenefitPlansAdjustmentSettlementGainLossMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:PensionPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMemberus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-01-012023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2022-01-012022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2021-01-012021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2023-01-012023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2022-01-012022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember2021-01-012021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:AccumulatedDefinedBenefitPlansAdjustmentCurtailmentGainLossAttributabletoParentMember2023-01-012023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:AccumulatedDefinedBenefitPlansAdjustmentCurtailmentGainLossAttributabletoParentMember2022-01-012022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:AccumulatedDefinedBenefitPlansAdjustmentCurtailmentGainLossAttributabletoParentMember2021-01-012021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-01-012023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDMember2022-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDMember2022-12-310001755672us-gaap:OtherPensionPlansDefinedBenefitMember2023-01-012023-12-310001755672us-gaap:OtherPensionPlansDefinedBenefitMember2022-01-012022-12-310001755672us-gaap:OtherPensionPlansDefinedBenefitMember2021-01-012021-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2022-08-310001755672us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-08-310001755672us-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:U.S.PlanswithPlanAssetsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:U.S.PlanswithPlanAssetsMember2022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:U.S.PlanswithPlanAssetsMember2023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:U.S.PlanswithPlanAssetsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:NonU.S.planswithplanassetsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:NonU.S.planswithplanassetsMember2022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:NonU.S.planswithplanassetsMember2023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:NonU.S.planswithplanassetsMember2022-12-310001755672ctva:AllotherplansMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672ctva:AllotherplansMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:AllotherplansMember2023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:AllotherplansMember2022-12-310001755672ctva:TrustAgreementMember2023-12-310001755672ctva:TrustAgreementMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberus-gaap:OtherAssetsMember2022-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310001755672ctva:PensionandotherpostemploymentbenefitsnoncurrentMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672ctva:PensionandotherpostemploymentbenefitsnoncurrentMemberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672ctva:PensionandotherpostemploymentbenefitsnoncurrentMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-12-310001755672ctva:PensionandotherpostemploymentbenefitsnoncurrentMemberus-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-12-310001755672us-gaap:EquitySecuritiesMembercountry:US2023-12-310001755672us-gaap:EquitySecuritiesMembercountry:US2022-12-310001755672us-gaap:EquitySecuritiesMemberus-gaap:NonUsMember2023-12-310001755672us-gaap:EquitySecuritiesMemberus-gaap:NonUsMember2022-12-310001755672us-gaap:FixedIncomeSecuritiesMember2023-12-310001755672us-gaap:FixedIncomeSecuritiesMember2022-12-310001755672us-gaap:HedgeFundsMember2023-12-310001755672us-gaap:HedgeFundsMember2022-12-310001755672us-gaap:PrivateEquityFundsMember2023-12-310001755672us-gaap:PrivateEquityFundsMember2022-12-310001755672us-gaap:RealEstateMember2023-12-310001755672us-gaap:RealEstateMember2022-12-310001755672us-gaap:CashAndCashEquivalentsMember2023-12-310001755672us-gaap:CashAndCashEquivalentsMember2022-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2023-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2023-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMember2023-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMember2023-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMember2023-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:RealEstateMember2023-12-310001755672us-gaap:OtherInvestmentsMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:OtherInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:OtherInvestmentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:OtherInvestmentsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2023-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:USTreasuryAndGovernmentMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310001755672ctva:PlanAssetsTotalInvestmentsMeasuredAtNAVMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:PensionTrustReceivablesMember2023-12-310001755672ctva:PensionTrustPayablesMemberus-gaap:PensionPlansDefinedBenefitMember2023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CommonStockMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2023-12-310001755672us-gaap:CommonStockMember2023-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:DefinedBenefitPlanCashMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasuryAndGovernmentMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:USTreasuryAndGovernmentMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:USTreasuryAndGovernmentMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:AssetBackedSecuritiesMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMember2022-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:RealEstateMember2022-12-310001755672ctva:DerivativeAssetMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672ctva:DerivativeAssetMemberus-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672ctva:DerivativeAssetMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672ctva:DerivativeAssetMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherContractMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherContractMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:OtherContractMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherContractMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:FairValueInputsLevel1Memberus-gaap:PensionPlansDefinedBenefitMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:USTreasuryAndGovernmentMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:HedgeFundsMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:RealEstateMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueMeasuredAtNetAssetValuePerShareMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:PensionTrustReceivablesMemberctva:OtherReconcilingItemsMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672ctva:PensionTrustPayablesMemberus-gaap:PensionPlansDefinedBenefitMemberctva:OtherReconcilingItemsMemberus-gaap:FairValueInputsLevel12And3Member2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CommonStockMemberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:CommonStockMember2022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMember2021-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:RealEstateMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherContractMember2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMember2022-01-012022-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:RealEstateMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherContractMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesUsMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:DefinedBenefitPlanEquitySecuritiesNonUsMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:HedgeFundsMember2023-01-012023-12-310001755672us-gaap:PrivateEquityFundsMemberus-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:RealEstateMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherContractMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Member2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberus-gaap:FairValueInputsLevel3Memberus-gaap:OtherContractMember2023-12-310001755672us-gaap:NonqualifiedPlanMemberctva:TrustAgreementMember2022-01-012022-12-310001755672us-gaap:NonqualifiedPlanMemberctva:TrustAgreementMember2023-01-012023-12-310001755672ctva:U.S.RetirementSavingsPlanMember2023-01-012023-12-310001755672ctva:U.S.RetirementSavingsPlanMember2022-01-012022-12-310001755672ctva:U.S.RetirementSavingsPlanMember2021-01-012021-12-310001755672ctva:CortevaOtherContributionPlansMember2023-01-012023-12-310001755672ctva:CortevaOtherContributionPlansMember2022-01-012022-12-310001755672ctva:CortevaOtherContributionPlansMember2021-01-012021-12-310001755672ctva:OIPMember2023-12-310001755672us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001755672us-gaap:EmployeeStockOptionMember2022-01-012022-12-310001755672us-gaap:EmployeeStockOptionMember2021-01-012021-12-310001755672ctva:OIPMemberus-gaap:StockOptionMemberctva:GrantsBetweenJune2019And2020Member2023-01-012023-12-310001755672ctva:Grantsbetween2016and2018Memberctva:EIPMemberus-gaap:StockOptionMember2023-01-012023-12-310001755672ctva:DowMember2023-01-012023-12-310001755672ctva:OIPMemberus-gaap:EmployeeStockMember2023-01-012023-12-310001755672ctva:OIPMemberus-gaap:EmployeeStockMember2022-01-012022-12-310001755672ctva:OIPMemberus-gaap:EmployeeStockMember2021-01-012021-12-310001755672ctva:OIPMember2023-01-012023-12-310001755672ctva:OIPMember2022-01-012022-12-310001755672ctva:OIPMember2021-01-012021-12-310001755672us-gaap:StockOptionMember2022-12-310001755672us-gaap:StockOptionMember2022-01-012022-12-310001755672us-gaap:StockOptionMember2023-01-012023-12-310001755672us-gaap:StockOptionMember2023-12-310001755672ctva:OIPMember2023-01-012023-12-310001755672ctva:OIPMember2022-01-012022-12-310001755672ctva:OIPMember2021-01-012021-12-310001755672ctva:OIPMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001755672us-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001755672us-gaap:PerformanceSharesMember2023-01-012023-12-310001755672srt:ManagementMembersrt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001755672srt:ManagementMembersrt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember2023-01-012023-12-310001755672ctva:PerformanceShareUnitsMember2023-01-012023-12-310001755672ctva:RestrictedStockUnitsAndPerformanceShareUnitsMember2022-12-310001755672ctva:RestrictedStockUnitsAndPerformanceShareUnitsMember2023-01-012023-12-310001755672ctva:RestrictedStockUnitsAndPerformanceShareUnitsMember2023-12-310001755672ctva:RSUsAndPSUsOIPMember2023-01-012023-12-310001755672ctva:RSUsAndPSUsOIPMember2022-01-012022-12-310001755672ctva:RSUsAndPSUsOIPMember2021-01-012021-12-310001755672ctva:RSUsAndPSUsOIPMember2023-12-310001755672us-gaap:CashEquivalentsMember2023-12-310001755672us-gaap:CashEquivalentsMember2022-12-310001755672ctva:MarketableSecuritiesMember2023-12-310001755672ctva:MarketableSecuritiesMember2022-12-310001755672us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001755672us-gaap:CommodityContractMember2023-01-012023-12-310001755672us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001755672us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001755672us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001755672us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310001755672us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001755672us-gaap:CommodityContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-310001755672us-gaap:ForeignExchangeContractMember2023-01-012023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2020-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-12-31iso4217:EUR0001755672us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2023-12-310001755672us-gaap:CommodityContractMemberus-gaap:NondesignatedMember2023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310001755672us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310001755672us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001755672us-gaap:CommodityContractMemberus-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-12-310001755672us-gaap:DesignatedAsHedgingInstrumentMember2021-01-012021-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-01-012023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2022-01-012022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2021-01-012021-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2023-01-012023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2022-01-012022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2021-01-012021-12-310001755672us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2023-01-012023-12-310001755672us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2022-01-012022-12-310001755672us-gaap:CommodityContractMemberus-gaap:NondesignatedMemberus-gaap:CostOfSalesMember2021-01-012021-12-310001755672us-gaap:CommodityContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2023-01-012023-12-310001755672us-gaap:CommodityContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2022-01-012022-12-310001755672us-gaap:CommodityContractMemberus-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:NondesignatedMember2021-01-012021-12-310001755672us-gaap:NondesignatedMember2023-01-012023-12-310001755672us-gaap:NondesignatedMember2022-01-012022-12-310001755672us-gaap:NondesignatedMember2021-01-012021-12-310001755672us-gaap:AvailableforsaleSecuritiesMember2021-01-012021-12-310001755672us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-12-310001755672us-gaap:CommodityContractMemberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310001755672country:US2023-01-012023-12-310001755672country:US2022-01-012022-12-310001755672country:US2021-01-012021-12-310001755672country:CA2023-01-012023-12-310001755672country:CA2022-01-012022-12-310001755672country:CA2021-01-012021-12-310001755672us-gaap:EMEAMember2023-01-012023-12-310001755672us-gaap:EMEAMember2022-01-012022-12-310001755672us-gaap:EMEAMember2021-01-012021-12-310001755672srt:LatinAmericaMember2023-01-012023-12-310001755672srt:LatinAmericaMember2022-01-012022-12-310001755672srt:LatinAmericaMember2021-01-012021-12-310001755672srt:AsiaPacificMember2023-01-012023-12-310001755672srt:AsiaPacificMember2022-01-012022-12-310001755672srt:AsiaPacificMember2021-01-012021-12-310001755672country:BR2023-01-012023-12-310001755672country:BR2022-01-012022-12-310001755672country:BR2021-01-012021-12-310001755672country:US2023-12-310001755672country:US2022-12-310001755672country:US2021-12-310001755672country:CA2023-12-310001755672country:CA2022-12-310001755672country:CA2021-12-310001755672us-gaap:EMEAMember2023-12-310001755672us-gaap:EMEAMember2022-12-310001755672us-gaap:EMEAMember2021-12-310001755672srt:AsiaPacificMember2023-12-310001755672srt:AsiaPacificMember2022-12-310001755672srt:AsiaPacificMember2021-12-310001755672srt:LatinAmericaMember2023-12-310001755672srt:LatinAmericaMember2022-12-310001755672srt:LatinAmericaMember2021-12-310001755672ctva:SeedMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310001755672ctva:CropProtectionMemberus-gaap:OperatingSegmentsMember2023-01-012023-12-310001755672us-gaap:OperatingSegmentsMember2023-01-012023-12-310001755672ctva:SeedMemberus-gaap:OperatingSegmentsMember2023-12-310001755672ctva:CropProtectionMemberus-gaap:OperatingSegmentsMember2023-12-310001755672us-gaap:OperatingSegmentsMember2023-12-310001755672ctva:SeedMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310001755672ctva:CropProtectionMemberus-gaap:OperatingSegmentsMember2022-01-012022-12-310001755672us-gaap:OperatingSegmentsMember2022-01-012022-12-310001755672ctva:SeedMemberus-gaap:OperatingSegmentsMember2022-12-310001755672ctva:CropProtectionMemberus-gaap:OperatingSegmentsMember2022-12-310001755672us-gaap:OperatingSegmentsMember2022-12-310001755672ctva:SeedMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310001755672ctva:CropProtectionMemberus-gaap:OperatingSegmentsMember2021-01-012021-12-310001755672us-gaap:OperatingSegmentsMember2021-01-012021-12-310001755672ctva:SeedMemberus-gaap:OperatingSegmentsMember2021-12-310001755672ctva:CropProtectionMemberus-gaap:OperatingSegmentsMember2021-12-310001755672us-gaap:OperatingSegmentsMember2021-12-310001755672us-gaap:MaterialReconcilingItemsMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMember2021-01-012021-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:SeedMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:CropProtectionMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberus-gaap:CorporateMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:A2022RestructuringActionsMemberctva:SeedMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:A2022RestructuringActionsMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:A2022RestructuringActionsMemberctva:CropProtectionMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:A2022RestructuringActionsRussiaExitMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:SeedMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberus-gaap:CorporateMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:A2022RestructuringActionsMemberctva:SeedMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:A2022RestructuringActionsMember2022-01-012022-12-310001755672ctva:SeedMemberctva:A2022RestructuringActionsRussiaExitMemberus-gaap:SettlementWithTaxingAuthorityMember2022-01-012022-12-310001755672ctva:A2022RestructuringActionsRussiaExitMemberus-gaap:SettlementWithTaxingAuthorityMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:SeedMemberctva:A2022RestructuringActionsRussiaExitMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:A2022RestructuringActionsRussiaExitMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:SeedMember2021-01-012021-12-310001755672us-gaap:MaterialReconcilingItemsMemberus-gaap:CorporateMember2021-01-012021-12-310001755672ctva:EIDPMember2022-01-012022-12-310001755672ctva:EIDPMember2021-01-012021-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:PensionPlansDefinedBenefitMemberctva:EIDPMember2021-01-012021-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMemberctva:EIDPMember2021-01-012021-12-310001755672ctva:EIDPMember2023-12-310001755672ctva:EIDPMember2022-12-310001755672us-gaap:RelatedPartyMemberctva:EIDPMember2023-12-310001755672us-gaap:RelatedPartyMemberctva:EIDPMember2022-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDPMember2023-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDPMember2022-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDPMember2023-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDPMember2022-12-310001755672ctva:EIDMember2023-12-310001755672ctva:EIDMember2022-12-310001755672ctva:EIDPMember2021-12-310001755672ctva:EIDPMember2020-12-310001755672us-gaap:PreferredStockMemberctva:EIDPMember2020-12-310001755672us-gaap:CommonStockMemberctva:EIDPMember2020-12-310001755672us-gaap:AdditionalPaidInCapitalMemberctva:EIDPMember2020-12-310001755672us-gaap:RetainedEarningsMemberctva:EIDPMember2020-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMemberctva:EIDPMember2020-12-310001755672us-gaap:NoncontrollingInterestMemberctva:EIDPMember2020-12-310001755672us-gaap:RetainedEarningsMemberctva:EIDPMember2021-01-012021-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMemberctva:EIDPMember2021-01-012021-12-310001755672us-gaap:AdditionalPaidInCapitalMemberctva:EIDPMember2021-01-012021-12-310001755672us-gaap:PreferredStockMemberctva:EIDPMember2021-12-310001755672us-gaap:CommonStockMemberctva:EIDPMember2021-12-310001755672us-gaap:AdditionalPaidInCapitalMemberctva:EIDPMember2021-12-310001755672us-gaap:RetainedEarningsMemberctva:EIDPMember2021-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMemberctva:EIDPMember2021-12-310001755672us-gaap:NoncontrollingInterestMemberctva:EIDPMember2021-12-310001755672us-gaap:RetainedEarningsMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:NoncontrollingInterestMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:AdditionalPaidInCapitalMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:PreferredStockMemberctva:EIDPMember2022-12-310001755672us-gaap:CommonStockMemberctva:EIDPMember2022-12-310001755672us-gaap:AdditionalPaidInCapitalMemberctva:EIDPMember2022-12-310001755672us-gaap:RetainedEarningsMemberctva:EIDPMember2022-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMemberctva:EIDPMember2022-12-310001755672us-gaap:NoncontrollingInterestMemberctva:EIDPMember2022-12-310001755672us-gaap:RetainedEarningsMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:NoncontrollingInterestMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:AdditionalPaidInCapitalMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:PreferredStockMemberctva:EIDPMember2023-12-310001755672us-gaap:CommonStockMemberctva:EIDPMember2023-12-310001755672us-gaap:AdditionalPaidInCapitalMemberctva:EIDPMember2023-12-310001755672us-gaap:RetainedEarningsMemberctva:EIDPMember2023-12-310001755672us-gaap:AccumulatedOtherComprehensiveIncomeMemberctva:EIDPMember2023-12-310001755672us-gaap:NoncontrollingInterestMemberctva:EIDPMember2023-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDMember2023-01-012023-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDMember2022-01-012022-12-310001755672ctva:A4.50SeriesPreferredStockMemberctva:EIDMember2021-01-012021-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDMember2023-01-012023-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDMember2022-01-012022-12-310001755672ctva:A3.50SeriesPreferredStockMemberctva:EIDMember2021-01-012021-12-310001755672ctva:EIDMember2023-01-012023-12-310001755672ctva:CortevaMemberctva:EIDPMember2022-12-310001755672ctva:CortevaMemberctva:EIDPMember2023-01-012023-12-310001755672ctva:CortevaMemberctva:EIDPMember2022-01-012022-12-310001755672ctva:CortevaMemberctva:EIDPMember2021-01-012021-12-310001755672ctva:CortevaMemberctva:EIDPMember2023-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMemberctva:CortevaMemberctva:EIDPMember2023-12-310001755672ctva:AccruedandOtherCurrentLiabilitiesMemberctva:CortevaMemberctva:EIDPMember2022-12-310001755672us-gaap:OtherNoncurrentLiabilitiesMemberctva:CortevaMemberctva:EIDPMember2023-12-310001755672us-gaap:OtherNoncurrentLiabilitiesMemberctva:CortevaMemberctva:EIDPMember2022-12-310001755672us-gaap:SegmentContinuingOperationsMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:SegmentContinuingOperationsMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:SegmentContinuingOperationsMemberctva:EIDPMember2021-01-012021-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:EIDPMember2023-01-012023-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:EIDPMember2022-01-012022-12-310001755672us-gaap:MaterialReconcilingItemsMemberctva:EIDPMember2021-01-012021-12-31
2023

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-K
(Mark One)
 ANNUAL REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the fiscal year ended December 31, 2023
OR
 TRANSITION REPORT PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from _______ to _______
___________________________________________________________________________

Commission File Number 001-38710
Corteva, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware 82-4979096
(State or other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)
9330 Zionsville Road,Indianapolis,Indiana46268 (833)267-8382
974 Centre Road,Wilmington,Delaware19805
(Address of Principal Executive Offices) (Zip Code)(Registrant’s Telephone Number, including area code)
Commission File Number 1-815
EIDP, Inc.
(Exact Name of Registrant as Specified in Its Charter)
Delaware 51-0014090
(State or other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.)
9330 Zionsville Road,Indianapolis,Indiana46268 (833)267-8382
974 Centre Road,Wilmington,Delaware19805
(Address of Principal Executive Offices) (Zip Code)(Registrant’s Telephone Number, including area code)

Securities registered pursuant to Section 12(b) of the Act for Corteva, Inc.:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, par value $0.01 per shareCTVANew York Stock Exchange

Securities registered pursuant to Section 12(b) of the Act for EIDP, Inc.:
Title of each classTrading Symbol(s)Name of each exchange on which registered
$3.50 Series Preferred Stock CTAPrANew York Stock Exchange
$4.50 Series Preferred StockCTAPrBNew York Stock Exchange

No securities are registered pursuant to Section 12(g) of the Act.
_____________________________________________________

Indicate by check mark if the registrant is a well-known seasoned issuer (as defined in Rule 405 of the Securities Act).    
Corteva, Inc.YesxNoo
EIDP, Inc.YesxNoo

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.   
Corteva, Inc.YesoNox
EIDP, Inc.YesoNox



Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 
Corteva, Inc.YesxNoo
EIDP, Inc.YesxNoo

         Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit files). 
Corteva, Inc.YesxNoo
EIDP, Inc.YesxNoo

         Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Corteva, Inc.Large Accelerated Filerx
Accelerated Filer o
Non-Accelerated Filero
Smaller reporting company o
Emerging growth company o
EIDP, Inc.Large Accelerated Filero
Accelerated Filer o
Non-Accelerated Filerx
Smaller reporting company o
Emerging growth company o

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Corteva, Inc.o
EIDP, Inc.o

Indicate by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C.7262(b)) by the registered public accounting firm that prepared or issued its audit report.
Corteva, Inc.YesxNoo
EIDP, Inc.YesxNoo

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements.
Corteva, Inc.o
EIDP, Inc.o

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b).
Corteva, Inc.o
EIDP, Inc.o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).    
Corteva, Inc.YesoNox
EIDP, Inc.YesoNox

The aggregate market value of voting stock of Corteva, Inc. held by non-affiliates of the registrant (excludes outstanding shares beneficially owned by directors and officers and treasury shares) as of June 30, 2023 was $40.6 billion.

As of February 1, 2024, 701,783,000 shares of Corteva, Inc's common stock, $0.01 par value, were outstanding.

As of February 1, 2024, all of EIDP, Inc.’s issued and outstanding common stock, comprised of 200 shares, $0.30 par value per share, is held by Corteva, Inc.


EIDP, Inc. meets the conditions set forth in General Instruction I(1)(a), (b) and (d) of Form 10-K (as modified by a grant of no-action relief dated February 12, 2018) and is therefore filing this form with reduced disclosure format.

Documents Incorporated by Reference

Information pertaining to certain Items in Part III of this report is incorporated herein by reference to portions of Corteva, Inc.'s definitive 2022 Annual Meeting Proxy Statement to be filed within 120 days after the end of the year covered by this Annual Report on Form 10-K, pursuant to Regulation 14A (the Proxy).



CORTEVA, INC.
Form 10-K
Table of Contents
  Page
  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
 
 
 
 
  
 
F-83
 
F-70

1

Explanatory Note

This Annual Report on Form 10-K is a combined report being filed separately by Corteva, Inc. and EIDP, Inc. ("EIDP"). Corteva, Inc. owns all of the common equity interests in EIDP, and EIDP meets the conditions set forth in General Instruction I(1)(a), (b) and (d) of Form 10-K and is therefore filing its information within this Form 10-K with the reduced disclosure format. Each of Corteva, Inc. and EIDP is filing on its own behalf the information contained in this report that relates to itself, and neither company makes any representation as to information relating to the other company. Where information or an explanation is provided that is substantially the same for each company, such information or explanation has been combined in this report. Where information or an explanation is not substantially the same for each company, separate information and explanation has been provided. In addition, separate consolidated financial statements for each company, along with notes to the consolidated financial statements, are included in this report. 

The primary differences between Corteva and EIDP's financial statements relate to EIDP's Preferred Stock - $4.50 Series and EIDP's Preferred Stock - $3.50 Series, a related party loan between EIDP and Corteva, Inc. and the associated tax deductible interest expense for EIDP, a Master In-House Banking Agreement between EIDP and Corteva, Inc., including certain consolidated subsidiaries, and the capital structure of Corteva. Inc. (See EIDP's Note 1 - Basis of Presentation to EIDP's Consolidated Financial Statements, for additional information for above items). The separate EIDP financial statements and footnotes for areas that differ from Corteva, are included within this Annual Report on Form 10-K and begin on page F-74. Footnotes of EIDP that are identical to that of Corteva are cross-referenced accordingly.

2

ITEM 1.  BUSINESS
Unless otherwise indicated or the context otherwise requires, references in this Annual Report on Form 10-K to:
"Corteva" or "the company" refers to Corteva, Inc. and its consolidated subsidiaries (including EIDP);
"EIDP" refers to EIDP, Inc. (formerly known as E. I. du Pont de Nemours and Company) and its consolidated subsidiaries or EIDP, Inc. excluding its consolidated subsidiaries, as the context may indicate;
"DowDuPont" refers to DowDuPont Inc. and its subsidiaries prior to the Separation (as defined below) of Corteva;
"Historical Dow" refers to The Dow Chemical Company and its consolidated subsidiaries prior to the Internal Reorganization as defined below;
"Historical DuPont" and "Historical EID" refers to EIDP prior to the Internal Reorganization (as defined below);
"Dow" refers to Dow Inc. after The Dow Distribution (as defined below);
"DuPont" refers to DuPont de Nemours, Inc. after the Separation of Corteva; and
"Merger" refers to the all-stock merger of equals strategic combination between Historical Dow and Historical DuPont.

Background
Corteva is a leading global provider of seed and crop protection solutions focused on the agriculture industry and contributing to a healthier, more secure and sustainable food supply. Corteva was incorporated in Delaware in March 2018 and maintains its business headquarters in Indianapolis, Indiana. With one of the broadest and most productive new product pipelines in the agriculture industry, Corteva is focused on progressing science-based innovations, which aim to deliver a wide range of improved agriculture products and services to its customers. The company leverages its rich heritage of scientific achievement to advance its robust innovation pipeline and continue to shape the future of responsible agriculture. New products are crucial to solving farmers’ productivity challenges amid a growing global population while addressing natural resistance, regulatory changes, safety requirements and competitive dynamics. The company’s investment in technology-based and solution-based product offerings allows it to meet farmers’ evolving needs while ensuring that its investments generate sufficient returns. Meanwhile, through Corteva’s unique routes to market, the company continues to work face-to-face with farmers around the world to understand their needs.

The company's broad portfolio of agriculture solutions fuels farmer productivity in approximately 125 countries. See Note 22 - Geographic Information, to the Consolidated Financial Statements for details on the location of the company's sales and property.

On June 1, 2019, Corteva, Inc. became an independent, publicly traded company through the completed separation (the “Separation”) of the agriculture business of DuPont de Nemours, Inc. (formerly known as DowDuPont Inc.) (“DuPont” or "DowDuPont"). The Separation was effectuated through a pro rata distribution (the “Corteva Distribution”) of all of the then- issued and outstanding shares of common stock of Corteva, Inc.

As a result of the Internal Reorganization (defined below), on May 31, 2019, EIDP was contributed to Corteva, Inc. and, as a result, Corteva, Inc. owns 100% of the outstanding common stock of EIDP. Shares of EIDP preferred stock, $3.50 Series and $4.50 Series, issued and outstanding immediately prior to the Separation remain issued and outstanding and were unaffected by the Separation. EIDP is a subsidiary of Corteva, Inc. and continues to be a reporting company, subject to the requirements of the Securities Exchange Act of 1934, as amended. Prior to March 31, 2019, Corteva, Inc. had engaged in no business operations and had no assets or liabilities of any kind, other than those incident to its formation.

Internal Reorganizations and Business Separations
Subsequent to the Merger, Historical Dow and EIDP engaged in a series of internal reorganization and realignment steps to realign their businesses into three subgroups: agriculture, materials science and specialty products ("Internal Reorganization"). On April 1, 2019, DowDuPont completed the separation of its materials science business into a separate and independent public company by way of a distribution of Dow common stock, to holders of DowDuPont's common stock (the “Dow Distribution” and together with the Corteva Distribution, the “Distributions”).

On April 1, 2019, Historical Dow entities, which held certain assets and liabilities aligned with Historical Dow’s agriculture business and the assets and liabilities associated with its specialty products business, respectively, were transferred and conveyed to DowDuPont.

3

Part I
ITEM 1.  BUSINESS, continued

On April 1, 2019 and May 1, 2019, EIDP’s materials science and specialty products entities, along with their respective assets and liabilities, were conveyed to Dow and DowDuPont, respectively. On May 2, 2019, DowDuPont conveyed Historical Dow agricultural entities to EIDP.

On May 6, 2019, the Board of Directors of DowDuPont approved the distribution of all the then issued and outstanding shares of common stock of Corteva, Inc., then a wholly-owned subsidiary of DowDuPont, to DowDuPont stockholders. On May 31, 2019, DowDuPont contributed EIDP to Corteva, Inc. and on June 1, 2019, the Separation was completed. Corteva, Inc.'s common stock began trading on the New York Stock Exchange under the ticker symbol "CTVA" on June 3, 2019.

Separation Agreements
In connection with the Distributions, DuPont, Corteva, and Dow (together, the “Parties” and each a “Party”) have entered into certain agreements to effect the separation, provide for the allocation of DowDuPont’s assets, employees, liabilities and obligations (including its investments, property and employee benefits and tax-related assets and liabilities) among the Parties, and provide a framework for Corteva's relationship with Dow and DuPont following the separations and Distributions. The Parties entered into the following agreements:
Separation and Distribution Agreement - Effective April 1, 2019, the Parties entered into an agreement that sets forth, among other things, the principal transactions necessary to effect the Distributions, as well as the agreements that govern certain aspects of the Parties’ ongoing relationships after the completion of the Distributions (the "Corteva Separation Agreement").
Tax Matters Agreement - The Parties entered into an agreement effective as of April 1, 2019, as amended on June 1, 2019, that governs their respective rights, responsibilities and obligations with respect to tax liabilities and benefits, tax attributes, the preparation and filing of tax returns, the control of audits and other tax proceedings and other matters regarding taxes.
Employee Matters Agreement - The Parties entered into an agreement effective as of April 1, 2019, that identifies employees and employee-related liabilities (and attributable assets) allocated (either retained, transferred and accepted, or assigned and assumed, as applicable) to the Parties as part of the Distributions.
Intellectual Property Cross-License Agreement - Effective as of April 1, 2019 Corteva and Dow, and effective June 1, 2019, Corteva and DuPont, entered into Intellectual Property Cross-License Agreements. The Intellectual Property Cross-License Agreements set forth the terms and conditions under which the applicable Parties may use in their respective businesses, following each of the Distributions, certain know-how (including trade secrets), copyrights, and software, and certain patents and standards, allocated to another Party pursuant to the Corteva Separation Agreement.
Letter Agreement - Effective as of June 1, 2019 DuPont and Corteva entered into a Letter Agreement. The Letter Agreement sets forth certain additional terms and conditions related to the Separation, including certain limitations on each party’s ability to transfer certain businesses and assets to third parties without assigning certain of such party’s indemnification obligations under the Corteva Separation Agreement to the other party to the transferee of such businesses and assets or meeting certain other alternative conditions.

Business Segments
The company’s operations are managed through two reportable segments: seed and crop protection. The seed segment develops and supplies commercial seed combining superior germplasm with advanced traits to produce high yield potential for farmers around the world. The crop protection segment supplies products to protect crop yields against weeds, insects and disease, enabling farmers to achieve optimal results. The combination of these leading platforms creates one of the broadest portfolios of agriculture solutions in the industry. Additional information with respect to business segment results is included in Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, on page 40 of this report and Note 23 - Segment Information, to the Consolidated Financial Statements.




4

Part I
ITEM 1.  BUSINESS, continued

Seed
The seed segment is a global leader in developing and supplying commercial seed combining advanced germplasm and traits that produce optimum yield for farms around the world. The company’s seed segment is a leader in many key seed markets, including North America corn and soybeans, Europe corn and sunflower, as well as Brazil, India, South Africa and Argentina corn. The company offers trait technologies that improve resistance to weather, disease, insects and enhance food and nutritional characteristics, herbicides used to control weeds, and digital solutions that assist farmer decision-making to help maximize yield and profitability.

A summary of the seed segment’s net sales by major product line and geographic region (based on customer location) are as follows:
9987 9989
Products and Brands
The seed segment’s major brands and technologies, by key product line, are listed below:
Seed Solutions Brands
Pioneer® seeds; Brevant® seeds; Dairyland Seed®; Hoegemeyer® hybrids; Nutech® seed; Seed Consultants®; AgVenture® brand; Cordius®, Licensing Division of Corteva Agriscience, DUO® hybrid corn, NEXSEM® corn, NordTM semillas; PhytoGen® cotton; Pannar™ brand corn
Seed Solutions Traits and Technologies
ENLIST™ corn; ENLIST E3™ soybeans; ENLIST™ cotton; Enlist™ weed control system; EXZACT® Precision Technology; Herculex™ Insect Protection; Herculex™ XTRA Insect Protection; Leptra® insect protection technology offering protection against above ground pests; PowerCore® corn, PowerCore® Ultra corn, PowerCore® Enlist™ corn, PowerCore® Ultra Enlist™ corn, POWERCORE® trait technology family of products; Optimum® AcreMax® family of products offering above and below ground insect protection; REFUGE ADVANCED® trait technology; SMARTSTAX® trait technology; NEXERA® canola trait; Omega-9 Oils; Pioneer® brand Optimum® AQUAmax® products; Pioneer® brand A-Series soybeans; Pioneer® brand Plenish® high oleic soybeans; ExpressSun herbicide tolerant trait; Pioneer Protector® products for canola, sunflower and sorghum; Pioneer MAXIMUS® rapeseed hybrids; Qrome® corn; Clearfield® canola; PROPOUND™ advanced canola meal; Vorceed™ Enlist™ products; Conkesta®; Conkesta E3® soybeans; WideStrike™ Insect Protection; WideStrike™ 3 Insect Protection; Inzen® trait; BOLT® technology; STS® herbicide tolerant trait; MAXIMUS® canola hybrids; CottonBest® program; Brevant™ Protector products; Optimum® GLY herbicide tolerance trait Optimum® AcreMax® insect protection; Optimum® AcreMax® Leptra® insect protection; Optimum® AcreMax® Xtra insect protection; Optimum® AcreMax® XTreme insect protection; Bovalta® BMR products; Optimum® Intrasect® insect protection; Optimum® Leptra® insect protection
Other
LumiGEN™ seed treatments; Lumisena™; Lumiverd™; Lumiscend™; Lumiscend™ Pro; Lumisure®; Lumiflex™; Lumiante™; LumiTreo™; Dermacor™ X-100; Vertisan® ST; Lumiderm®; Lumivia™ CPL; Lumivia™ and Lumialza®

5

Part I
ITEM 1.  BUSINESS, continued

In connection with the validation of breeding plans and large-scale product development timelines focused on rapidly ramping up differentiated technology solutions, in 2019 the company began accelerating the ramp up of the Enlist E3TM trait platform in the company’s soybean portfolio mix across all brands, including Pioneer® brands. During the five year ramp-up period, the company began to significantly reduce the volume of products with the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits beginning in 2021, with expected minimal use of the Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® traits thereafter for the remaining term of the non-exclusive license with the Monsanto Company. Refer to Prepaid Royalties within the Critical Accounting Estimates section on page 55 for additional information.

Distribution
The seed segment has a diverse worldwide network which markets and distributes the company’s brands to customers, primarily through the company’s multi-channel, multi-brand strategy, which includes four differentiated channels: Pioneer agency model, regional brands, retail brands, as well as third parties through licensing and distribution channels.

The Pioneer agency model is unique to Corteva and represents sales made directly to farmers via independent sales representatives. Through this agency model, the company interacts directly with farmers at multiple points in the growing season, from prior to planting all the way through harvest. These regular interactions enable the company to provide the advice and service farmers need while giving the company real-time insights into the customers’ future ordering decisions. The company’s regional brands connect to customers through regional brand employees and farmer-dealer networks. Retail brands provide a one-stop shop for seed and chemistry solutions and may include sales to distributors, agricultural cooperatives, and dealers. Finally, Corteva out-licenses traits and germplasm to third parties.

Key Raw Materials
The key raw materials for seed include corn and soybean seeds. To produce high-quality seeds, the company contracts with third-party growers globally. Corteva focuses on production close to the customer to provide the seed product, which is suitable for that region and its weed, insect and disease challenges, weather, soil and other conditions. The company conditions and packages the seeds using its own plants and third-party contract manufacturers. By striking a balance between owning production facility assets directly and contracting with third-party growers, the company believes it is best able to maintain flexibility to react to demand changes unique to each geography while minimizing costs. The company seeks to collaborate with strategic seed growers and share its digital agronomy and product management knowledge with them. The company’s third-party growers are an important part of its supply chain. Corteva provides them with rigorous training, planning tools and access to a system that tests and advances products matched to specific geographic needs.

The seed segment's research and development ("R&D") and supply chain groups work seamlessly to select and maintain product characteristics that enhance the quality of its seed products and solutions. Corteva focuses on customer-driven innovation to deliver superior germplasm and trait technologies. With its large sets of digitized data and its seed field management solution, the company can manage its field operations efficiently and draw insights from data quickly and effectively. This allows the company’s supply chain to react quickly to changing customer needs and provides R&D with tremendous amounts of data to analyze and incorporate into resource allocation decisions. The company continues to invest in and build capabilities that drive value via data digitization and analytics that enable it to create an even more responsive and efficient answer to customer needs.

Crop Protection
The crop protection segment serves the global agricultural input industry with products that protect against weeds, insects and other pests, and disease, and that improve overall crop health both above and below ground via nitrogen management and seed-applied technologies. The segment's crop protection solutions and digital solutions provide farmers the tools they need to improve productivity and profitability, and help keep fields free of weeds, insects and diseases. The company is a leader in global herbicides, insecticides, nitrogen stabilizers, pasture and range management herbicides and biologicals.

6

Part I
ITEM 1.  BUSINESS, continued

A summary of the crop protection segment’s net sales by major product line and geographic region (based on customer location) are as follows:
15276 15278
Products and Brands
The crop protection segment’s major brands and technologies, by key product line, are listed below:
Insect and Nematode Management
CLOSER™; DELEGATE®; INTREPID®; ISOCLAST™; EXALT™; PEXALON™; TRANSFORM™; VYDATE®; OPTIMUM®; Reklemel™; SALIBRO™; PYRAXALT™; QALCOVA™; JEMVELVA™; RADIANT™; SENTRICON®; ENTRUST® SC; GF-120™; and TRACER™
Disease Management
APROACH PRIMA®; VESSARYA®; APROACH®; APROACH POWER®; VIOVAN®; TALENDO™; VERBEN®, EQUATION PRO®; EQUATION CONTACT®; ZORVEC™; INATREQ™; CURZATE™; TANOS®, BIMTM MAX; BEAMTM; FONTELIS™; ACANTO™; GALILEO®; VERPIXOTM; and ZETIGOTM PRM
Weed Control
ARIGO®; ARYLEX®; ENLIST™ weed control system; ENLIST ONE™; BROADWAY™; RINSKOR™; MUSTANG®; GALLANT™; VERDICT®; KERB®; PIXXARO®; QUELEX™; KORVETTO®; REXADE™; GALLERY®; SNAPSHOT®; GRANITE®; PINDAR® GT; VIPER®; BELKAR®; WIDEMATCH®; PERFECTMATCH®; CLINCHER™; GARLON™; TORDON™; REMEDY™; PASTAR™; SONIC®; TEXARO®; KEYSTONE®; PACTO®; LIGATE®; DIMENSION®; TOPSHOT™; RICER®; LOYANT™; ROYANT™; JAGUAR™; AGIXATM, NOVIXID®, NOVLECT™; REALM® Q; LONTREL®; GRAZON®; PAXEO®; RESICORE®; SPIDER®; STARANETM; and SURESTART®
Nitrogen Management
INSTINCT®; N-SERVE® Nitrogen Stabilizer
Other
LANDVisor™

Key Raw Materials
The key raw materials and supplies for crop protection include chlorinated pyridines derivatives, specialty intermediates and technical grade active ingredients, chlorine, and seed treatments. Typically, the company purchases major raw materials through long-term contracts with multiple suppliers, which sometimes require minimum purchase commitments. Certain important raw materials are supplied by a few major suppliers. The company expects the markets for its raw materials to remain balanced. The company relies on contract manufacturers, both domestically and internationally, to produce certain inputs or key components for its product formulations. These inputs are sourced globally and the company generally formulates its products close to its end customers. Shifts in customer demand, reduced local availability of raw materials, and/or production capacity constraints may, at times, necessitate sourcing from an alternative geography. The company strives to maintain multiple high-quality supply sources for each input.


7

Part I
ITEM 1.  BUSINESS, continued

Corteva’s supply chain strategy involves managing global supplies of active and intermediate ingredients sourced regionally with global best practices and oversight. Corteva’s supply strategy includes a robust and flexible global footprint to meet future portfolio growth. The company’s supply chain also provides competitive advantages including reducing time to meet customer requirements in regions while minimizing costs through the value chain.

Seasonality
Corteva’s sales are generally strongest in the first half of the calendar year, which aligns with the planting and growing season in the northern hemisphere. The company typically generates about 65 percent of its sales in the first half of the calendar year, driven by northern hemisphere seed and crop protection sales. The company generates about 35 percent of its sales in the second half of the calendar year, led by seed sales in the southern hemisphere. The seasonality in sales impacts both the seed and crop protection segments. The company’s direct distribution channel, where products are shipped to farmers, is more affected by planting delays than its competitors. Generally speaking, unfavorable weather slows the planting season and can affect the company’s quarterly results and sales mix. Severe unfavorable weather, however, can impact overall sales. Accounts receivable tends to be higher during the first half of the year, consistent with the peak sales period in the northern hemisphere, with cash collection focused in the fourth quarter.

Human Capital Management
Corteva aims to attract the best employees, to retain those employees through offering career development and training opportunities while also prioritizing their safety and wellness in an inclusive and productive work environment. The company’s strong employee base of approximately 22,500 employees, along with its commitment to Corteva’s core values, is a key element to the success of its business.

Workforce Composition. As of December 31, 2023, the company globally employs approximately 22,500 employees. In order to address regional specific customer needs within its global business, the company has a geographically diverse employee base with 46%, 22%, 19%, and 13% located in North America, Latin America, EMEA, and Asia-Pacific regions, respectively.

Approximately 2% of the workforce is unionized in the United States and another 12% participate in work councils and collective bargaining arrangements outside the United States. In 2023, the company did not experience any work stoppages due to strike or lockouts.

Safety. Living safely is one of the company’s core values by which the company manages its business. The company has implemented safety programs and management practices to promote a culture of safety to protect its employees, as well as the environment. This includes required trainings for employees, as well as specific qualifications and certifications for certain operational employees.

Inclusion. The company has a robust inclusion, diversity, and equity (“ID&E”) vision and strategy, based upon the belief that embracing diversity and inclusion benefits the company by creating a workforce with a greater variety of skills and perspectives as a result of their differentiated backgrounds and experiences. Specific ID&E initiatives are identified and tracked to create a culture of belonging that is designed to create an environment where the best talent is attracted, retained, and engaged. Management is expected to support specific inclusion initiatives for their respective geographies and business, as applicable, in order to build a more inclusive working environment for the benefit of all employees. Critical to creating this environment are company-sponsored employee business resource groups (“BRGs”) that support and promote certain mutual objectives of both the employee and the company, including community engagement and the professional development of employees. The BRGs are open to all employees and provide a space where employees can foster connections within a supportive environment. The company maintains nine global BRGs, each led by a member of the company’s senior leadership: Disability Awareness Network; Global African Heritage Alliance; Global Indigenous Peoples Alliance; Growing Asian Impact Network; Latin Network; Pride (LGBTQ+); Professional Learning Acceleration Network; Veteran’s Network; and Women’s Inclusion Network.

The company monitors its recruitment and talent development processes, in order to prevent and detect inequities and potentially discriminatory practices that could negatively impact the creation of an inclusive culture and the retention of key talent for our leadership pipeline. The company reviews its ID&E efforts through periodic engagement surveys and other measures. The results of the company’s efforts, along with its ID&E strategy, are reviewed periodically with the company’s management, and through annual reviews of the company’s leadership pipelines and ID&E programs with the People and Compensation Committee of the Board of Directors.

8

Part I
ITEM 1.  BUSINESS, continued


Experienced Management. The company believes its management team has the experience necessary to effectively execute its strategy and advance its product pipelines and technology. The company's chief executive officer and business presidents have an average of approximately 25 years of agriculture experience and are supported by an experienced and talented management team who is dedicated to maintaining and expanding its position as a global force in the agriculture industry.

Intellectual Property
Corteva considers its intellectual property estate, which includes patents, trade secrets, trademarks and copyrights, in the aggregate, to constitute a valuable asset of Corteva and actively seeks to secure intellectual property rights as part of an overall strategy to protect its investment in innovations and maximize the results of its research and development program. While the company believes that its intellectual property estate, taken as a whole, provides a competitive advantage in many of its businesses, no single patent, trademark, license or group of related patents or licenses is in itself essential to the company as a whole or to any of the company’s segments.

Trade secrets are an important element of the company's intellectual property. Many of the processes used to make Corteva products are kept as trade secrets which, from time to time, may be licensed to third parties. Corteva vigilantly protects all of its intellectual property including its trade secrets. When the company discovers that its trade secrets have been unlawfully taken, it reports the matter to governmental authorities for investigation and potential criminal action, as appropriate. In addition, the company takes measures to mitigate any potential impact, which may include civil actions seeking redress, restitution and/or damages based on loss to the company and/or unjust enrichment.

Patents & Trademarks.  Corteva continually applies for and obtains U.S. and foreign patents and has access to a large patent portfolio, both owned and licensed. Corteva’s rights under these patents and licenses, as well as the products made and sold under them, are important to the company in the aggregate. The protection afforded by these patents varies based on country, scope of individual patent coverage, as well as the availability of legal remedies in each country. This significant patent estate may be leveraged to align with the company’s strategic priorities within and across product lines. At December 31, 2023, the company owned about 5,900 U.S. patents and about 11,500 active patents outside of the U.S.

Remaining life of granted patents owned as of December 31, 2023:
Approximate U.S.Approximate Other Countries
Within 5 years1,0002,000
6 to 10 years2,0003,600
11 to 15 years1,9005,500
16 to 20 years1,000400
Total5,90011,500

In addition to its owned patents, the company owns over 4,400 patent applications.

The company also owns or has licensed a substantial number of trade names, trademarks and trademark registrations in the United States and other countries, including approximately 12,200 registrations and 1,000 pending trademark applications in a number of jurisdictions.

In addition, the company holds multiple long-term biotechnology trait licenses from third parties in the normal course of business. Most corn hybrids and soybean varieties sold to customers contain biotechnology traits licensed from third parties under these long-term licenses.

Competition
The company competes with producers of seed germplasm, trait developers, and crop protection products on a global basis. The global market for products within the industry is highly competitive and the company believes competition has and will continue to intensify. Corteva competes based on germplasm and trait leadership, price, quality and cost competitiveness and the offering of a holistic solution. The company’s key competitors include BASF, Bayer, FMC, Syngenta and ChemChina, as well as companies trading in generic crop protection chemicals and regional seed companies.


9

Part I
ITEM 1.  BUSINESS, continued


Environmental Matters
Information related to environmental matters is included in several areas of this report: (1) Environmental Proceedings beginning on page 27; (2) Management's Discussion and Analysis of Financial Condition and Results of Operations beginning on pages 58-60; and (3) Note 2 - Summary of Significant Accounting Policies, and Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

Regulatory Considerations
Our seed and crop protection products and operations are subject to certain approval procedures, manufacturing requirements and environmental protection laws and regulations in the jurisdictions in which we operate. We evaluate and test products throughout the research and development phases, and each new technology undergoes further rigorous scientific studies and tests to validate that the product can be used effectively and that use of the technology is safe for humans and animals and does not cause undue harm to the environment when used in accordance with the directions for use.

The regulatory approval processes and procedures globally are becoming increasingly more complex, which has resulted in additional testing needs, longer approval timelines that are difficult to predict, and higher development and maintenance costs. We continue to invest on an ongoing basis to keep dossiers current, respond to regulators and meet evolving regulatory standards required by global regulatory frameworks. Failure to comply with these regulations or future regulatory bans and requirements related to our products and their use may materially impact our financial performance. The increase in timelines for regulatory approvals may result in the company not achieving its sustainability targets, or its anticipated returns on research and development investments.

Regulation of Genetically Modified Organisms (“GMOs”) and Gene Editing
Genetically modified seed products are subject to regulatory approval processes and procedures. For example, in the United States, the Coordinated Framework for Regulation of Biotechnology governs genetically modified or gene edited organisms, using existing U.S. legislation and legal authorities on food, feed and environmental safety. Plant GMOs are regulated by the U.S. Department of Agriculture’s (the “USDA”) Animal and Plant Health Inspection Service (the “APHIS”) under the Plant Protection Act. The APHIS assesses the trait to ensure that the trait will not pose a plant pest and is not a noxious weed. GMOs in food are regulated by the Food and Drug Administration (the “FDA”) under the Federal Food, Drug, and Cosmetic Act (the “FFDCA”). The FDA ensures that the food is safe for food and feed. Pesticides and microorganisms containing GMOs are regulated by the Environmental Protection Agency (the “EPA”) pursuant to the Federal Insecticide, Fungicide and Rodenticide Act (the “FIFRA”) and the Toxic Substances Control Act. The EPA assesses the trait or the stack containing the traits to ensure that there is no unreasonable adverse effect to the environment.

Other countries also have rigorous approval processes, procedures, and scientific testing requirements for the cultivation or import of genetically modified seed products and gene editing technology. In the United States and other countries that have functioning regulatory systems, a rigorous scientific review is conducted by these agencies to demonstrate that genetically modified and gene edited products are as safe as traditionally bred, non-biotech/GMO counterparts for food, feed and the environment. Various countries in EMEA, Latin America, and Asia Pacific have banned GMOs entirely.

Regulation of Crop Protection Products
Globally, manufacturers of crop protection products, including herbicides, fungicides and insecticides are required to submit an application/dossier and obtain government regulatory approval prior to selling products in a particular country. In the United States, the EPA is responsible for registering and overseeing the approval and marketing of pesticides, pursuant to the FIFRA, the FFDCA and the Food Quality Protection Act. Also, the USDA and the FDA monitor levels of pesticide residue that is allowed on or in crops. Already registered pesticides are required to be re-registered every 15 years to ensure that those products continue to meet the rigorous safety standards set by the regulators. The EPA reevaluates pesticide tolerances at least every 10 years, taking into account ecological and human health risks, in addition to cumulative risks as a result of multiple routes and sources of exposure.

Beginning in January 2022, before registering any new conventional pesticide active ingredient, the EPA evaluates the potential effects on listed species and their designated critical habitats under the Endangered Species Act (the “ESA”). The EPA also has initiated such evaluations for certain other active ingredients in response to existing or threatened litigation. Where the EPA determines that a pesticide in the registration and re-evaluation processes “may affect” a listed species, the EPA must consult with the U.S. Fish and Wildlife Service and the National Marine Fisheries Service. As part of its approval, registration, and reevaluation processes, the EPA may impose certain use restrictions on crop protection products under the ESA. Under the
10

Part I
ITEM 1.  BUSINESS, continued

citizen suit provisions, the ESA also includes citizen suit provisions that allow the public to bring suit in court against federal agencies when they believe a listed species is not being adequately protected by the EPA. FIFRA contains similar provisions that allow the public to challenge an EPA’s registration decision. These lawsuits may subject products to additional use limitations and labeling requirements and further studies, as well as result in registrations being revoked, in whole or in part.

The company's European operations are subject to the European chemical regulation REACH (“Registration, Evaluation, Authorisation, and Restriction of Chemicals”) and the CLP (“Classification, Labeling, and Packaging of Substances and Mixtures”). Other jurisdictions also have rigorous approval processes, procedures and scientific testing requirements for the approval of crop protection products. We continue to monitor legislative and regulatory developments related to pollution and other environmental health and safety matters.

Available Information
The company's annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K, and amendments to those reports are accessible on Corteva's website at http://investors.corteva.com by clicking on the section labeled "Financial Information", then on "SEC Filings." These reports are made available, without charge, as soon as is reasonably practicable after the company files or furnishes them electronically with the Securities and Exchange Commission. No portion of the company's website mentioned in this report, or the materials contained on it, have been made part of this annual report on Form 10-K or incorporated herein by reference, unless such incorporation is specifically mentioned herein.

11

Part I
ITEM 1A.  RISK FACTORS

Risks Related to our Industry

Corteva may not be able to obtain or maintain the necessary regulatory approvals for some of its products, including its seed and crop protection products, which could restrict its ability to sell those products in some markets.

Regulatory and legislative requirements affect the development, manufacture and distribution of Corteva’s products, including the testing and planting of seeds containing Corteva’s biotechnology traits and the import of crops grown from those seeds, and non-compliance can harm Corteva’s sales and profitability.

Seed products incorporating biotechnology derived traits and crop protection products must be extensively tested for safety, efficacy and environmental impact before they can be registered for production, use, sale or commercialization in a given market. In certain jurisdictions, Corteva must periodically renew its approvals for both biotechnology and crop protection products, which typically require Corteva to demonstrate compliance with then-current standards which generally are more stringent since the prior registration. The regulatory approvals process is lengthy, costly, complex and in some markets unpredictable, with requirements that can vary by product, technology, industry and country. The regulatory approvals process for products that incorporate novel modes of action or new technologies can be particularly unpredictable and uncertain due to the then-current state of regulatory guidelines and objectives, as well as governmental policy considerations and non- governmental organization and other stakeholder considerations. The uncertainty and increased length of regulatory approvals may reduce Corteva’s return on its research and development investments, and impede its ability to meet sales, profitability, or sustainability metrics.

Furthermore, the detection of biotechnology traits or chemical residues from a crop protection product not approved in the country in which Corteva sells or cultivates its product, or in a country to which Corteva imports its product, may affect Corteva’s ability to supply or export its products, or even result in crop destruction, product recalls or trade disruption, which could result in lawsuits and termination of licenses related to biotechnology traits and raw material supply agreements. Delays in obtaining regulatory approvals to import, including those related to the importation of crops grown from seeds containing certain traits or treated with specific chemicals, may influence the rate of adoption of new products in globally traded crops.

Additionally, the regulatory environment may be impacted by the activities of non-governmental organizations and special interest groups and stakeholder reaction to actual or perceived impacts of new and existing technology, products or processes on safety, health and the environment. Obtaining and maintaining regulatory approvals requires submitting a significant amount of information and data, which may require participation from technology providers. Regulatory standards and trial procedures are continuously changing. In addition, Corteva has seen an increase in recent years in the number of lawsuits filed by those who identify themselves as public or environmental interest groups seeking to invalidate pesticide product registrations and/or challenge the way federal or state governmental entities apply the rules and regulations governing pesticide produce use. The pace of change together with the lack of regulatory harmony could result in unintended noncompliance. Responding to these changes and meeting existing and new requirements may involve significant costs or capital expenditures or require changes in business practice that could result in reduced profitability. The failure to receive necessary permits or approvals could have near- and long-term effects on Corteva’s ability to produce and sell some current and future products.

The successful development and commercialization of Corteva's pipeline products will be necessary for Corteva's growth.

Corteva uses advanced breeding technologies to produce hybrids and varieties with superior performance in farmers’ fields and uses biotechnology to introduce traits that enhance specific characteristics of its crops. Corteva also uses advanced analytics, software tools, mobile communications and new planting and monitoring equipment to provide agronomic recommendations to growers. Additionally, Corteva conducts research into biological and chemical products to protect farmers’ crops from pests and diseases and enhance plant productivity.

New product concepts may be abandoned for many reasons, including greater anticipated development costs, technical difficulties, lack of efficacy, regulatory obstacles or inability to market under regulatory frameworks, competition, inability to prove the original concept, lack of demand and the need to divert focus, from time to time, to other initiatives with perceived opportunities for better returns. The processes of active ingredient development or discovery, breeding, biotechnology trait discovery and development and trait integration are lengthy, and a very small percentage of the chemicals, genes and germplasm Corteva tests is selected for commercialization. Furthermore, the length of time and the risk associated with the breeding and biotech pipelines are interlinked because both are required as a package for commercial success in markets where
12

Part I
ITEM 1A.  RISK FACTORS, continued

biotech traits are approved for growers, since seed hybrids and varieties could require modification to tolerate higher doses and/or new varieties of herbicides and pesticides as weeds and insects develop resistance. Commercial transitions to the company’s new technologies can take several years to complete, and weed and insect resistance may develop faster than Corteva can respond with new technologies or enhancements to existing technologies. In countries where biotech traits are not approved for widespread use, Corteva’s seed sales depend on the quality of its germplasm. While initial commercialization efforts have been promising, there are no guarantees that anticipated levels of product acceptability within Corteva's markets will be achieved or that higher quality products will not be developed by Corteva's competitors in the future.

Speed in discovering, developing, protecting and responding to new technologies, including artificial intelligence and new technology-based distribution channels that accelerate Corteva’s product development timelines and could facilitate its ability to engage with customers and end users, and bringing related products to market is a significant competitive advantage. Commercial success frequently depends on being the first company to the market, and many of Corteva’s competitors are also making considerable investments in similar new biotechnology products, improved germplasm products, biological and chemical products and agronomic recommendation products.

The degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products and technologies can affect Corteva’s sales and results of operations by affecting planting approvals, regulatory requirements and customer purchase decisions.

Concerns and claims regarding the safe use of seeds with biotechnology traits and crop protection products in general, and their potential impact on health and the environment reflect a growing trend in societal demands for increasing levels of product safety and environmental protection. These include concerns and claims that increased use of crop protection products, drift, inversion, volatilization and the use of biotechnology traits meant to reduce the resistance of weeds or pests to control by crop protection products, could increase or accelerate such resistance and otherwise negatively impact health and the environment. These and other concerns could manifest themselves in stockholder proposals, preferred purchasing, delays or failures in obtaining or retaining regulatory approvals, delayed product launches, lack of market acceptance, product discontinuation, litigation, continued pressure for and adoption of more stringent regulatory intervention, termination of raw material supply agreements and legal claims. These and other concerns could also influence public perceptions, the viability or continued sales of certain of Corteva’s products, Corteva’s reputation and the cost to comply with regulations. As a result, such concerns could have a material adverse effect on Corteva’s business, results of operations, financial condition and cash flows.

Changes in agricultural and related policies of governments and international organizations may prove unfavorable.

In many markets there are various pressures to reduce government subsidies to farmers, which may inhibit the growth in these markets of products used in agriculture. In addition, government programs that create incentives for farmers, including those established by the U.S. Farm Bill, may be modified or discontinued. However, it is difficult to predict accurately whether, and if so when, such changes will occur. Corteva expects that the policies of governments and international organizations will continue to affect the planting choices made by growers as well as the income available to growers to purchase products used in agriculture and, accordingly, the operating results of the agriculture industry.

The costs of complying with evolving regulatory requirements could negatively impact Corteva’s business, results of operations and financial condition. Actual or alleged violations of environmental laws or permit requirements could result in restrictions or prohibitions on plant operations, substantial civil or criminal sanctions, as well as the assessment of strict liability and/or joint and several liability.

Corteva is subject to extensive federal, state, local and foreign laws, regulations, rules and ordinances relating to pollution, protection of the environment, waste water discharges, the generation, storage, handling, transportation, treatment, disposal and remediation of hazardous substances and waste materials and the use of genetically modified seeds and crop protection active ingredients by growers.

Environmental and health and safety laws, regulations and standards, including those with respect to PFAS and other substances, expose Corteva to the risk of substantial costs and liabilities, including liabilities associated with Corteva’s business and the discontinued and divested businesses and operations of EIDP. As is typical for businesses like Corteva’s, soil and groundwater contamination has occurred in the past at certain sites and may be identified at other sites in the future. Disposal of waste from Corteva’s business at off-site locations also exposes it to potential remediation costs. Consistent with past practice, Corteva is continuing to monitor, investigate and remediate soil and groundwater contamination at several of these sites.
13

Part I
ITEM 1A.  RISK FACTORS, continued


Costs and capital expenditures relating to environmental, health or safety matters are subject to evolving regulatory requirements and depend on the timing of the promulgation and enforcement of specific standards which impose the requirements. Moreover, changes in environmental regulations, including those related to climate change, could inhibit or interrupt Corteva’s operations, or require modifications to its facilities in the future. Accordingly, environmental, health or safety regulatory matters could result in significant unanticipated costs or liabilities, which may be materially higher than Corteva’s accruals.

Climate change and unpredictable seasonal and weather factors could impact Corteva’s sales and earnings.

The agriculture industry is subject to seasonal and weather factors, which can vary unpredictably from period to period. Weather factors can affect the presence of disease and pests on a regional basis and, accordingly, can positively or adversely affect the demand for crop protection products, including the mix of products used or the level of returns. The weather also can affect supply chains and the quality, volume and cost of seed produced for sale as well as demand and product mix. Seed yields can be higher or lower than planned, which could lead to higher inventory and related write-offs. Climate change may increase the frequency or intensity of extreme weather such as storms, floods, heat waves, droughts and other events that could affect the quality, volume and cost of seed produced for sale as well as demand and product mix. Climate change may also affect the availability and suitability of arable land and contribute to unpredictable shifts in the average growing season and types of crops produced.

Corteva’s business is subject to various competition and antitrust, rules and regulations around the world, and as the size of its business grows, scrutiny of its business by legislators and regulators in these areas may intensify.

On July 9, 2021, President Biden issued an executive order promoting competition in the American economy. The order encouraged further examination and efforts by U.S. regulatory agencies to avoid market concentrations for agricultural inputs, that could challenge the survival of family farms. The executive order also directs the U.S. Secretary of Agriculture to take action to ensure that the intellectual property system, while still incentivizing innovation, does not also unnecessarily reduce competition in seed and other agricultural input markets beyond what is reasonably contemplated by the U.S. Patent Act and propose strategies for addressing those concerns across intellectual property, antitrust, and other relevant laws. While the ultimate impact of the executive order will depend on the actions ultimately resulting from the U.S. regulatory authorities, actions taken by such authorities may increase the regulation and regulatory costs associated with the agriculture industry in the future and restrict the company from pursuing certain growth opportunities, including mergers and acquisitions.

Scrutiny from regulators in the U.S. and abroad may intensify as Corteva’s business presence grows. This scrutiny and related investigations, even when not resulting in an enforcement action, may result in damage to a company’s reputation, significant defense expense, as well as become a distraction to management. Antitrust and competition enforcement actions, including the current FTC and related state attorney general lawsuits pending against Corteva, may result in regulators imposing fines, penalties, or restrictions on a company’s business practices in a manner that may significantly impact its results of operations.

Corteva participates in an industry that is highly competitive and has undergone consolidation, which could increase competitive pressures.

Corteva currently faces significant competition in the markets in which it operates. In most segments of the market, the number of products available to the grower is steadily increasing as new products are introduced. At the same time, certain products are coming off patent and are thus available to generic manufacturers for production and commercialization. Upon the loss or expiration of patent protection for one of Corteva’s products or of a product that Corteva licenses, or upon the “at- risk” launch (despite pending patent infringement litigation against the generic product) by a generic manufacturer of a generic version of one of Corteva’s patented products or of a product that Corteva licenses, Corteva can lose a major portion of revenues for that product, which can have a material adverse effect on Corteva’s business. Additionally, data analytic tools and web-based new direct purchase models offer increased transparency and comparability, which creates price pressures. Corteva cannot predict the pricing or promotional actions of its competitors. Aggressive marketing or pricing by Corteva’s competitors could adversely affect Corteva’s business, results of operations and financial conditions. As a result, Corteva continues to face significant competitive challenges.


14

Part I
ITEM 1A.  RISK FACTORS, continued

Corteva’s sales to its customers may be adversely affected should a company successfully establish an intermediary platform for the sale of Corteva’s products or otherwise position itself between Corteva and its customers.

Corteva services customers in part through the Pioneer direct sales channel in key agricultural geographies, including the United States. In addition, Corteva supplements this approach with strong retail channels, including distributors, agricultural cooperatives and dealers, and with digital and data solutions that assist farmer decision-making with a view to optimize their product selection and maximize their yield and profitability. While Corteva expects its indirect channels will extend its reach and increase exposure of its products to other potential customers, including smaller farmers or farmers in less concentrated areas, there can be no assurance that Corteva will be successful in this regard. If a competitor were to successfully establish an intermediary platform for distribution of Corteva’s products, it may disrupt Corteva’s distribution model and inhibit Corteva’s ability to provide a complete go-to-market strategy covering the direct, dealer and retail channels. In such a circumstance, Corteva’s sales may be adversely affected.

Risks Related to Our Operations

Corteva is dependent on its relationships or contracts with third parties with respect to certain of its raw materials or licenses and commercialization.

Corteva is dependent on third parties in the research, development and commercialization of its products and enters into transactions including, but not limited to, supply agreements, licensing agreements, and manufacturing agreements in connection with Corteva’s business. The majority of Corteva’s corn hybrids and soybean varieties sold to customers contain biotechnology traits that Corteva licenses from third parties under long-term licenses. If Corteva loses its rights under such licenses, it could negatively impact Corteva’s ability to obtain future licenses on competitive terms, commercialize new products and generate sales from existing products. Corteva may elect to out-license its technology, including germplasm. There can be no guarantee that such out-licensing will not ultimately strengthen Corteva’s competition thereby adversely impacting Corteva’s results of operations.

While Corteva relies heavily on third parties for multiple aspects of its business and commercialization activities, Corteva does not control many aspects of such third parties’ activities. Third parties may not complete activities on schedule or in accordance with Corteva’s expectations. Failure by one or more of these third parties to meet their contractual or other obligations to Corteva or to comply with applicable laws or regulations, or any disruption in the relationship between Corteva and one or more of these third parties could delay or prevent the development, approval or commercialization of Corteva’s products and could also result in non-compliance or reputational harm, all with potential negative implications for Corteva’s business.

In addition, Corteva’s agreements with third parties may obligate it to meet certain contractual or other obligations to third parties. For example, Corteva may be obligated to meet certain thresholds or abide by certain boundary conditions. If Corteva were to fail to meet such obligations to the third parties, its relationship with such third parties may be disrupted. Such a disruption could negatively impact certain of Corteva’s licenses on which it depends, could cause reputational harm, and could negatively affect Corteva’s business, results of operations and financial condition.

Volatility in Corteva’s input costs, which include raw materials and production costs, could have a significant impact on Corteva’s business, results of operations and financial condition.

Corteva’s input costs are variable based on the costs associated with production or with raw materials Corteva uses. For example, Corteva’s production costs vary, especially on a seasonal basis where changes in weather influence supply and demand. In addition, Corteva’s manufacturing processes consume significant amounts of raw materials, the costs of which are subject to worldwide supply and demand as well as other factors beyond Corteva’s control. Corteva refers to these costs collectively as input costs. Significant variations in input costs affect Corteva’s operating results from period to period.

When possible, Corteva purchases raw materials through negotiated long-term contracts to minimize the impact of price fluctuations. Corteva also enters into over-the-counter and exchange traded derivative commodity instruments to hedge its exposure to price fluctuations on certain purchases. In addition, Corteva takes actions to offset the effects of higher input costs through selling price increases, productivity improvements and cost reduction programs. Success in offsetting higher input costs with price increases is largely influenced by competitive and economic conditions and could vary significantly depending on the market served. If Corteva is not able to fully offset the effects of higher input costs, it could have a significant impact on its financial results.
15

Part I
ITEM 1A.  RISK FACTORS, continued


Our business, financial condition and results of operations could be materially affected by disruptions in the global economy caused by geopolitical and military conflicts.

The global economy has been negatively impacted by the military conflict between Russia and Ukraine. While we have concluded our business activities in Russia, we have experienced shortages in materials, the inability to insure shipments, and increased costs for transportation, energy, and raw material and other inputs due in part to the negative impact of the Russia-Ukraine military conflict on the global economy. Further escalation of the military conflict or related geopolitical tensions, including increased trade barriers or restrictions on global trade, could result in, among other things, cyberattacks, further supply disruptions, and changes to foreign exchange rates and financial markets, any of which may adversely affect our business and supply chains. Such geopolitical instability and uncertainty has negatively impacted our ability to sell to, ship products to, collect payments from, and support customers in certain regions. Logistics restrictions, including closures of air space and shipping ports, the reduction of the availability of farmable land, and the destruction of facilities could further increase these adverse impacts and negatively impact demand for our products in the region.

Similar or more severe disruptions, trade barriers, business risks, asset seizures, and volatility in foreign exchange and financial markets could occur if tensions or conflicts between China and Taiwan, or other countries, escalate, or if the United States would become a party to such a military conflict. Currently, a material portion of the company’s crop protection inputs are sourced directly or indirectly from China. While the company utilizes dual- or multi- source supply chains to minimize business disruptions, these strategies may not be adequate to address the scope of disruptions created by such a conflict. Further escalation or expansion of economic disruption or in the scope of global or regional conflicts could have a material adverse effect on our results of operations.

Corteva’s business, results of operations and financial condition could be adversely affected by environmental, litigation and other commitments and contingencies.

As a result of Corteva’s operations, including past operations and those related to divested businesses and discontinued operations of EIDP, Corteva incurs environmental operating costs for pollution abatement activities including waste collection and disposal, installation and maintenance of air pollution controls and wastewater treatment, emissions testing and monitoring and obtaining permits. Corteva also incurs environmental operating costs related to environmental related research and development activities including environmental field and treatment studies as well as toxicity and degradation testing to evaluate the environmental impact of products and raw materials. In addition, Corteva maintains and periodically reviews and adjusts its accruals for probable environmental remediation and restoration costs.

Corteva expects to continue to incur environmental operating costs since it will operate global manufacturing, product handling and distribution facilities that are subject to a broad array of environmental laws and regulations. These rules are subject to change by the implementing governmental agency, which Corteva monitors closely. Corteva’s environmental policy requires that its operations fully meet or exceed legal and regulatory requirements. In addition, Corteva expects to continue certain voluntary programs, and could consider additional voluntary actions, to reduce air emissions, minimize the generation of hazardous waste, decrease the volume of water use and discharges, increase the efficiency of energy use and reduce the generation of persistent, bioaccumulative and toxic materials. Costs to comply with complex environmental laws and regulations, as well as internal voluntary programs and goals, are significant and Corteva expects these costs will continue to be significant for the foreseeable future. Over the long-term, such expenditures are subject to considerable uncertainty and could fluctuate significantly.

Corteva accrues for environmental matters when it is probable that a liability has been incurred and the amount can be reasonably estimated. As remediation activities vary substantially in duration and cost from site to site, it is difficult to develop precise estimates of future site remediation costs. Corteva expects to base such estimates on several factors, including the complexity of the geology, the nature and extent of contamination, the type of remedy, the outcome of discussions with regulatory agencies and other Potentially Responsible Parties (“PRPs”) at multi-party sites and the number of, and financial viability of, other PRPs. Considerable uncertainty exists with respect to environmental remediation costs and, under adverse changes in circumstances, the potential liability may be materially higher than Corteva’s accruals.

Corteva faces risks arising from various unasserted and asserted litigation matters arising out of the normal course of its current and former business operations, including intellectual property, commercial, product liability, environmental and antitrust lawsuits. Corteva has noted a trend in public and private suits being filed on behalf of states, counties, cities and utilities
16

Part I
ITEM 1A.  RISK FACTORS, continued

alleging harm to the general public and the environment, including waterways and watersheds. Claims alleging harm to the public and the environment may be brought against Corteva, notwithstanding years of scientific evidence and regulatory determinations supporting the safety of crop protection products. The litigation involving Monsanto’s Roundup® non-selective glyphosate containing weedkiller products has resulted in negative publicity and sentiment and may lead to similar suits with respect to glyphosate-containing products and/or other established crop protection products. Claims and allegations that Corteva’s products or products that Corteva manufactures or markets on behalf of third parties are not safe could result in litigation, damage to Corteva’s reputation and have a material adverse effect on Corteva’s business. It is not possible to predict the outcome of these various proceedings and any potential impact on Corteva. An adverse outcome in any one or more of these matters may result in losses not fully covered by Corteva's insurance policies, and could be material to Corteva's financial results. Various factors or developments can lead to changes in current estimates of liabilities. Such factors and developments may include, but are not limited to, additional data, safety or risk assessments, as well as a final adverse judgment, significant settlement or changes in applicable law. A future adverse ruling or unfavorable development could result in future charges that could have a material adverse effect on Corteva.

The company, pursuant to the respective Separation Agreements, is entitled to cost sharing and indemnification from Chemours, Dow and DuPont, as applicable, for certain litigation, environmental, workers’ compensation and other liabilities related to its historical operations. In connection with the recognition of liabilities related to these matters, Corteva records an indemnification asset when recovery is deemed probable. These estimates of recovery are subject to various factors and developments that could result in differences from future estimates or the actual recovery. As of December 31, 2023, the indemnification assets pursuant to the Chemours Separation Agreement and the Corteva Separation Agreement are in aggregate $104 million within accounts and notes receivable - net and $366 million within other assets in the company’s Consolidated Balance Sheet. Any failure by, or inability to pay, these liabilities in line with the indemnification provisions of the Separation Agreements may have a material adverse effect on Corteva and its financial condition and results of operations.

In the ordinary course of business, Corteva may make certain commitments, including representations, warranties and indemnities relating to current and past operations, including those related to divested businesses and issue guarantees of third-party obligations. If Corteva were required to make payments as a result, they could exceed the amounts accrued, thereby adversely affecting Corteva’s financial condition and results of operations.

Corteva’s operations outside the United States are subject to risks and restrictions, which could negatively affect Corteva’s business, results of operations and financial condition.

Corteva’s operations outside the United States are subject to risks and restrictions, including fluctuations in foreign-currency exchange rates; inflation; exchange and price control regulations; corruption risks; competitive restrictions; changes in local political or economic conditions; import and trade restrictions; import or export licensing requirements and trade policy; and other potentially detrimental domestic and foreign governmental practices or policies affecting U.S. companies doing business abroad. In addition, Corteva’s international operations are sometimes in countries with unstable governments, economic or fiscal challenges, military or political conflicts, local epidemics or pandemics, significant levels of crime and organized crime, or developing legal systems. This may increase the risk to the company's employees, subcontractors or other parties, and to other liabilities, such as property loss or damage to the company's products, and may affect Corteva's ability to safely operate in, or import into, or receive raw materials from these countries.

Additionally, Corteva’s ability to export its products and its sales outside the United States has been, and may continue to be adversely affected by significant changes in trade, tax or other policies, including the risk that other countries may retaliate through the imposition of their own trade restrictions and/or increased tariffs in response to substantial changes to U.S. trade and tax policies.

Although Corteva has operations throughout the world, Corteva’s sales outside the United States in 2023 were principally to customers in Brazil, Eurozone countries, and Canada. Further, Corteva’s largest currency exposures are the Brazilian Real, Canadian dollar, South African Rand, Swiss franc, European Euro ("EUR") and Argentine peso. Inflation, market uncertainty or an economic downturn in these geographic areas could reduce demand for Corteva’s products and result in decreased sales volume, which could have a negative impact on Corteva’s results of operations. In addition, changes in exchange rates may affect Corteva’s results of operations, financial condition and cash flows in future periods. Corteva actively manages currency exposures that are associated with net monetary asset positions and committed purchases.


17

Part I
ITEM 1A.  RISK FACTORS, continued

Failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives and other portfolio actions may not have the results anticipated.

From time to time Corteva evaluates acquisition candidates that may strategically fit Corteva’s business and/or growth objectives. If Corteva is unable to successfully integrate and develop acquired businesses, including its acquisitions and growth in biologicals, Corteva could fail to achieve expected increases in revenues and operating results, as well as anticipated synergies and cost savings which could have a material adverse effect on Corteva’s financial results. Corteva continually reviews its portfolio of assets for contributions to its objectives and alignment with its strategy. However, Corteva may not be successful in separating underperforming or non-strategic assets and gains or losses on the divestiture of, or lost operating income from, such assets, which may affect Corteva’s earnings. Moreover, Corteva might incur asset impairment charges related to acquisitions or divestitures that reduce its earnings. In addition, if the execution of these transactions, initiatives, or portfolio actions is not successful, it could adversely impact Corteva’s financial condition, cash flows and results of operations.

Corteva’s business, results of operations and financial condition could be adversely affected by industrial espionage and other disruptions to its supply chain, information technology or network systems.

Business and/or supply chain disruptions, plant and/or power outages and information technology system and/or network disruptions, regardless of cause including acts of sabotage, employee error or other actions, geo-political activity, military conflict, local epidemics or pandemics, weather events and natural disasters could seriously harm Corteva’s operations as well as the operations of its customers and suppliers. For example, a pandemic in locations where Corteva has significant operations, sales, or key suppliers could have a material adverse effect on Corteva’s results of operations. In addition, terrorist attacks and natural disasters have increased stakeholder concerns about the security and safety of chemical production and distribution.

Business and/or supply chain disruptions may also be caused by security breaches, which could include, for example, ransomware attacks and attacks on information technology and infrastructure by hackers, viruses, breaches due to employee error or actions or other disruptions. Corteva and/or its suppliers may fail to effectively prevent, detect and recover from these or other security breaches and, as a consequence, such breaches could result in misuse of Corteva’s assets, business disruptions, loss of property including trade secrets and confidential business information, legal claims or proceedings, reporting errors, processing inefficiencies, negative media attention, loss of sales and interference with regulatory and data privacy compliance.

Like most major corporations, Corteva is the target of industrial espionage, including cyber-attacks, from time to time. Corteva has determined that these incidents have resulted, and could result in the future, in unauthorized parties gaining access to certain confidential business information. However, to date, Corteva has not experienced any material financial impact, changes in the competitive environment or impact on business operations from these events. Although management does not believe that Corteva has experienced any material losses to date related to industrial espionage and security breaches, including cybersecurity incidents, there can be no assurance that Corteva will not suffer such losses in the future.

Corteva actively manages the risks within its control that could lead to business disruptions and security breaches. As these threats continue to evolve, particularly around cybersecurity and artificial intelligence, Corteva may be required to expend significant resources to enhance its control environment, processes, practices and other protective measures. Despite these efforts, such events could also have a material adverse effect on Corteva’s business, financial condition, results of operations and reputation. Additionally, any losses from such an event may be excluded from, or in excess of the coverages provided by Corteva's insurance policies.

Corteva’s customers may be unable to pay their debts to Corteva, which could adversely affect Corteva’s results.

Corteva offers its customers financing programs with credit terms generally less than one year from invoicing in alignment with the growing season. Due to these credit practices as well as the seasonality of Corteva’s operations, Corteva may need to issue short-term debt at certain times of the year to fund its cash flow requirements. Corteva’s customers may be exposed to a variety of conditions that could adversely affect their ability to pay their debts. For example, customers in economies experiencing an economic downturn or in a region experiencing adverse growing conditions may be unable to repay their obligations to Corteva, which could adversely affect Corteva’s results.


18

Part I
ITEM 1A.  RISK FACTORS, continued

Corteva’s liquidity, business, results of operations and financial condition could be impaired if it is unable to raise capital through the capital markets or short-term debt borrowings.

Any limitation on Corteva’s ability to raise money in the capital markets or through short-term debt borrowings could have a substantial negative effect on Corteva’s liquidity. Corteva’s ability to affordably access the capital markets and/or borrow short- term debt in amounts adequate to finance its activities could be impaired as a result of a variety of factors, including factors that are not specific to Corteva, such as a severe disruption of the financial markets and, in the case of debt securities or borrowings, interest rate fluctuations. Due to the seasonality of Corteva’s business and the credit programs Corteva may offer its customers, net working capital investment and corresponding debt levels will fluctuate over the course of the year.

Corteva regularly extends credit to its customers to enable them to purchase seeds or crop protection products at the beginning of the growing season. The customer receivables may be used as collateral for short-term financing programs. Any material adverse effect upon Corteva’s ability to own or sell such customer receivables, including seasonal factors that may impact the amount of customer receivables Corteva owns, may materially impact Corteva’s access to capital.

Corteva has additional agreements with financial institutions to establish programs that provide financing for select customers of Corteva’s seed and crop protection products in the United States, Latin America, Europe and Asia. The programs are renewed on an annual basis. In most cases, Corteva guarantees the extension of such credit to such customers. If Corteva is unable to renew these agreements or access the debt markets to support customer financing, Corteva’s sales may be negatively impacted, which could result in increased borrowing needs to fund working capital.

Corteva’s earnings, operations and business, among other things, will impact its credit ratings, costs and availability of financing. There can be no assurance that Corteva or EIDP will maintain its current or prospective credit ratings. A decrease in the ratings assigned to Corteva or EIDP by the ratings agencies may negatively impact Corteva’s liquidity, access to the debt capital markets and increase Corteva’s cost of borrowing and the financing of its seasonal working capital.

Increases in pension and other post-employment benefit plan funding obligations may adversely affect Corteva’s results of operations, liquidity or financial condition.

Through Corteva's ownership of EIDP, Corteva maintains EIDP defined benefit pension and other post-employment benefit plans. For some of these plans, including EIDP’s principal U.S. pension plan, Corteva continues as sponsor for the entire plan regardless of whether participants, including retirees, are or were associated with EIDP’s agriculture business. Corteva uses many assumptions in calculating its expected future payment obligations under these plans. Significant adverse changes in credit or market conditions could result in actual rates of returns on pension investments being lower than assumed. In addition, expected future payment obligations may be adversely impacted by changes in assumptions regarding participants, including retirees. In 2024, Corteva expects to contribute approximately $50 million to its pension plans other than the principal U.S. pension plan, and about $115 million for its other post-employment benefit ("OPEB") plans. While not anticipated for 2024, Corteva may make potential discretionary contributions to the principal U.S. pension plan. Corteva, furthermore, may be required to make significant contributions to its pension plans in the future, which could adversely affect Corteva’s results of operations, liquidity and financial condition.

Sentiment towards climate change and other environmental, social and governance matters could adversely affect our stock price, results of operations, and access to capital.

Since 2020, Corteva has maintained certain commitments, aspirations, targets and initiatives as part of its sustainability programs. Execution of these strategies and the achievements of Corteva’s sustainability aspirations and goals are subject to risk and uncertainties, many of which are out of its control. Failure to achieve its sustainability aspirations and goals within the currently projected costs and expected timeframes could damage Corteva’s reputation, customer and investor relationships, or its access to financing. Further, given investors' increased focus related to sustainability matters, such a failure could cause stockholders to reduce their ownership holdings, all of which, in turn could adversely affect Corteva’s business, financial condition, results of operations and cash flows and reduce its stock price.


19

Part I
ITEM 1A.  RISK FACTORS, continued

Global or regional health pandemics or epidemics could negatively impact the company's business, financial condition and results of operations.

Corteva's business, financial condition, and results of operations could be negatively impacted by pandemics or epidemics. The severity, magnitude and duration of the pandemics is uncertain, rapidly changing and difficult to predict. Future pandemics or epidemics and resulting illness, travel restrictions and workforce disruptions could impact Corteva's global supply chain, its operations and its routes to market or those of its suppliers, co-manufacturers, or customers/distributors. These disruptions or the company's failure to effectively respond to them could increase product or distribution costs, alter the timing of recognizing manufacturing costs, or impact the delivery of products to customers or their ability to pay.

Government-pandemic or epidemic responses, including stay at home orders, can significantly impact other economic activity and markets around the world. Future outbreaks or pandemics could negatively impact the company's business, financial condition, and results of operations in numerous ways, including but not limited to increased market volatility that impacts the company's hedging, financial forecasting, and liquidity, including its access to capital markets and delays or modifications to the company's strategic plans and productivity initiatives.

Risks Related to Our Intellectual Property

Enforcing Corteva’s intellectual property rights, or defending against intellectual property claims asserted by others, could materially affect Corteva’s business, results of operations and financial condition.

Intellectual property rights, including patents, plant variety protection, trade secrets, confidential information, trademarks, trade names and other forms of trade dress, are important to Corteva’s business. Corteva endeavors to protect its intellectual property rights in jurisdictions in which its products are produced or used and in jurisdictions into which its products are imported. However, Corteva may be unable to obtain protection for its intellectual property in key jurisdictions. Further, changes in government policies and regulations, including changes made in reaction to pressure from non-governmental organizations, or the public generally, could impact the extent of intellectual property protection afforded by such jurisdictions.

Corteva has designed and implemented internal controls to restrict use of, access to and distribution of its intellectual property. Despite these precautions, Corteva’s intellectual property is vulnerable to infringement, misappropriation and other unauthorized access, including through employee or licensee error or actions, theft and cybersecurity incidents, and other security breaches. When unauthorized access and use or counterfeit products are discovered, Corteva reports such situations to governmental authorities for investigation, as appropriate, and takes measures to mitigate any potential impact. Protecting intellectual property related to biotechnology is particularly challenging because theft is difficult to detect and biotechnology can be self-replicating.

Competitors are increasingly challenging intellectual property positions and the outcomes can be highly uncertain. Third parties may claim Corteva’s products violate their intellectual property rights. Defending such claims, even those without merit, could be time-consuming and expensive. In addition, any such claim could result in Corteva’s having to enter into license agreements, develop non-infringing products or engage in litigation that could be costly. If challenges are resolved adversely, it could negatively impact Corteva’s ability to obtain licenses on competitive terms, develop and commercialize new products and generate sales from existing products.

In addition, because of the rapid pace of technological change, the confidentiality of patent applications in some jurisdictions and/or the uncertainty in predicting the outcome of complex proceedings relating to ownership and the scope of patents relating to certain emerging technologies, competitors may be issued patents related to Corteva’s business unexpectedly. These patents could reduce the value of Corteva’s commercial or pipeline products or, to the extent they cover key technologies on which Corteva has relied, require Corteva to seek to obtain licenses (and Corteva cannot ensure it would be able to obtain such a license on acceptable terms) or cease using the technology, no matter how valuable to Corteva’s business.

Legislation and jurisprudence on patent protection is evolving and changes in laws could affect Corteva’s ability to obtain or maintain patent protection for, and otherwise enforce Corteva’s patents related to, its products.


20

Part I
ITEM 1A.  RISK FACTORS, continued

Corteva’s business may be adversely affected by the availability of counterfeit products.

A counterfeit product is one that has been deliberately and fraudulently mislabeled as to its identity and source. A counterfeit Corteva product, therefore, is one manufactured by someone other than Corteva, but which appears to be the same as an authentic Corteva product. The prevalence of counterfeit products is a significant and growing industry-wide issue due to a variety of factors, including, but not limited to, the following: the widespread use of the Internet, which has greatly facilitated the ease by which counterfeit products can be advertised, purchased and delivered to individual consumers; the availability of sophisticated technology that makes it easier for counterfeiters to make counterfeit products; and the relatively modest risk of penalties faced by counterfeiters compared to the large profits that can be earned by them from the sale of counterfeit products. Further, laws against counterfeiting vary greatly from country to country, and the enforcement of existing laws varies greatly from jurisdiction to jurisdiction. For example, in some countries, counterfeiting is not a crime; in others, it may result in only minimal sanctions. In addition, those involved in the distribution of counterfeit products use complex transport routes to evade customs controls by disguising the true source of their products.

Corteva’s global reputation makes its products prime targets for counterfeiting organizations. Counterfeit products pose a risk to consumer health and safety because of the conditions under which they are manufactured (often in unregulated, unlicensed, uninspected and unsanitary sites) as well as the lack of regulation of their contents. Failure to mitigate the threat of counterfeit products, which is exacerbated by the complexity of the supply chain, could adversely impact Corteva’s business by, among other things, causing the loss of consumer confidence in Corteva’s name and in the integrity of its products, potentially resulting in lost sales and an increased threat of litigation.

Corteva undertakes significant efforts to counteract the threats associated with counterfeit products, including, among other things, working with regulatory authorities and multinational coalitions to combat the counterfeiting of products and supporting efforts by law enforcement authorities to prosecute counterfeiters; assessing new and existing technologies to seek to make it more difficult for counterfeiters to copy Corteva’s products and easier for consumers to distinguish authentic from counterfeit products; working diligently to raise public awareness about the dangers of counterfeit products; working collaboratively with wholesalers, customs offices and law enforcement agencies to increase inspection coverage, monitor distribution channels and improve surveillance of distributors; and working with other members of an international trade association of agrochemical companies to promote initiatives to combat counterfeiting activity. No assurance can be given, however, that Corteva’s efforts and the efforts of others will be entirely successful, and the presence of counterfeit products may continue to increase.

Restrictions under the intellectual property cross-license agreements limit Corteva’s ability to develop and commercialize certain products and services and/or prosecute, maintain and enforce certain intellectual property.

The company is dependent to a certain extent on DuPont and Dow to maintain and enforce certain of the intellectual property licensed under the Intellectual Property Cross-License Agreements. For example, DuPont and Dow are responsible for filing, prosecuting and maintaining (at their respective discretion) patents on trade secrets and know-how that they each respectively license to Corteva. They also have the first right to enforce their respective trade secrets and know-how licensed to Corteva. If DuPont or Dow, as applicable, fails to fulfill its obligations or chooses to not enforce the licensed patents, trade secrets or know-how under the Intellectual Property Cross-License Agreements, the company may not be able to prevent competitors from making, using and selling competitive products and services.

In addition, Corteva’s use of the intellectual property licensed to it under the Intellectual Property Cross-License Agreements is restricted to certain fields, which could limit Corteva’s ability to develop and commercialize certain products and services. For example, the licenses granted to Corteva under the agreement will not extend to all fields of use that the company may decide to enter into in the future. These restrictions may make it more difficult, time consuming and/or expensive for Corteva to develop and commercialize certain new products and services, or may result in certain of its products or services being later to market than those of its competitors.


21

Part I
ITEM 1A.  RISK FACTORS, continued

Risks Related to The Separation

In connection with the Separation the company has assumed, and agreed to indemnify DuPont and Dow for, certain liabilities. If the company is required to make payments pursuant to these indemnities, the company may need to divert cash to meet those obligations and its financial results could be negatively impacted. In addition, DuPont and Dow will indemnify Corteva for certain liabilities. These indemnities may not be sufficient to insure the company against the full amount of liabilities it incurs, and DuPont and/or Dow, and/or their historical separated businesses, may not be able to satisfy their indemnification obligations in the future.

Pursuant to the Separation Agreement, the Employee Matters Agreement and the Tax Matters Agreement with DuPont and Dow, the company agreed to assume, and indemnify DuPont and Dow for, certain liabilities for uncapped amounts, which may include, among other items, associated defense costs, settlement amounts and judgments, as discussed further in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements and Part I - Item 3 - Legal Proceedings. Payments pursuant to these indemnities may be significant and could negatively impact the company’s business, particularly indemnities relating to certain litigation for Historical DuPont operations or its actions that could impact the tax-free nature of the Corteva Distribution. Third parties could also seek to hold the company responsible for any of the liabilities allocated to DuPont and Dow, including those related to DowDuPont’s specialty products and/or materials science businesses, respectively, and those related to discontinued and/or divested businesses and operations of Historical Dow, which have been allocated to Dow. DuPont and/or Dow, as applicable, will agree to indemnify Corteva for such liabilities, but such indemnities may not be sufficient to protect the company against the full amount of such liabilities. In addition, DuPont and/or Dow, as applicable, may not be able to fully satisfy their indemnification obligations with respect to the liabilities the company incurs. Even if the company ultimately succeeds in recovering from DuPont and/or Dow, as applicable, any amounts for which the company is held liable, the company may be temporarily required to bear these losses itself. Each of these risks could negatively affect the company’s business, financial condition, results of operations and cash flows.

Additionally, the company generally has assumed and is responsible for the payment of its share of (i) certain liabilities of DowDuPont relating to, arising out of or resulting from certain general corporate matters of DowDuPont, (ii) certain liabilities of Historical DuPont relating to, arising out of or resulting from general corporate matters of Historical DuPont and discontinued and/or divested businesses and operations of Historical DuPont, including its spin-off of Chemours, and (iii) certain separation expenses not otherwise allocated to DuPont or Dow (or allocated specifically to Corteva) pursuant to the Corteva Separation Agreement, and third parties could seek to hold Corteva responsible for DuPont’s or Dow’s share of any such liabilities. For more information, see Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements and Part I - Item 3 - Legal Proceedings. DuPont and/or Dow, as applicable, will indemnify Corteva for their share of any such liabilities; however, such indemnities may not be sufficient to protect Corteva against the full amount of such liabilities, and/or DuPont and/or Dow may not be able to fully satisfy their respective indemnification obligations. In addition, even if the company ultimately succeeds in recovering from DuPont and/or Dow any amounts for which the company is held liable in excess of its agreed share, the company may be temporarily required to bear these losses itself and may not be able to fully insure itself to cover these risks. Each of these risks could materially affect the company’s business, financial condition, results of operations and cash flows.

The Separation and related transactions may expose Corteva to potential liabilities arising out of state and federal fraudulent conveyance laws

Although the company received a solvency opinion from an investment bank confirming that the company and DuPont were each adequately capitalized following the Distribution, the Separation could be challenged under various state and federal fraudulent conveyance laws. In connection with fraudulent conveyances or transfers are generally defined to include transfers made or obligations incurred with the actual intent to hinder, delay or defraud current or future creditors or transfers made or obligations incurred for less than reasonably equivalent value when the debtor was insolvent, or that rendered the debtor insolvent, inadequately capitalized or unable to pay its debts as they become due. Any unpaid creditor could claim that DuPont did not receive fair consideration or reasonably equivalent value in the Separation and Corteva Distribution, and that the Separation and Corteva Distribution left DuPont insolvent or with unreasonably small capital or that DuPont intended or believed it would incur debts beyond its ability to pay such debts as they matured. Additionally, under its indemnity provisions of the Separation Agreement, the company could find its liabilities increased as a result of a court concluding that Historical DuPont, Historical Dow or DowDuPont executed a fraudulent conveyance in connection with divestitures and spin-offs of any one of their historical operations, including Chemours. If a court were to agree with such a plaintiff, then such court could void the Separation and Distribution as a fraudulent transfer or impose substantial liabilities on Corteva, which could materially
22

Part I
ITEM 1A.  RISK FACTORS, continued

adversely affect its financial condition and results of operations. Among other things, the court could return some of Corteva’s assets or shares of Corteva common stock to DuPont, provide DuPont with a claim for money damages against Corteva in an amount equal to the difference between the consideration received by DuPont and the fair market value of Corteva at the time of the Corteva Distribution, or require Corteva to fund liabilities of other companies involved in the Internal Reorganization for the benefit of creditors.

The Distribution is also subject to review under state corporate Distribution statutes. Under the Delaware General Corporation Law (the “DGCL”), a corporation may only pay dividends to its stockholders either (i) out of its surplus (net assets minus capital) or (ii) if there is no such surplus, out of its net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year. Although the Distribution was made out of DowDuPont’s surplus and the company received an opinion that DowDuPont has adequate surplus under Delaware law to declare the dividend of Corteva common stock in connection with the Corteva Distribution, there can be no assurance that a court will not later determine that some or all of the Corteva Distribution was unlawful.

The company is subject to continuing contingent tax-related liabilities of DowDuPont following the Distribution.

There are several significant areas where the liabilities of DowDuPont may become Corteva’s obligations either in whole or in part. For example, under the Code and the related rules and regulations, each corporation that was a member of DowDuPont’s consolidated tax reporting group during any taxable period or portion of any taxable period ending on or before the effective time of the Distribution is jointly and severally liable for the U.S. federal income tax liability of the entire consolidated tax reporting group for such taxable period. Additionally, to the extent that any subsidiary of Corteva was included in the consolidated tax reporting group of either Historical DuPont or Historical Dow for any taxable period or portion of any taxable period ending on or before the effective date of the Merger, such subsidiary is jointly and severally liable for the U.S. federal income tax liability of the entire consolidated tax reporting group of Historical DuPont or Historical Dow, as applicable, for such taxable period. In connection with the Distributions, on April 1, 2019, the company entered into the Tax Matters Agreement with DuPont and Dow that allocates the responsibility for prior period consolidated taxes among Corteva, DuPont and Dow. If DuPont or Dow were unable to pay any prior period taxes for which it is responsible, however, the company could be required to pay the entire amount of such taxes, and such amounts could be significant. Other provisions of federal, state, local, or foreign law may establish similar liability for other matters, including laws governing tax-qualified pension plans, as well as other contingent liabilities.

23

ITEM 1B.  UNRESOLVED STAFF COMMENTS

None.


ITEM 1C.  CYBERSECURITY
Risk Management and Strategy. The company’s risk management programs for cybersecurity are integrated into the company’s enterprise risk management and general compliance programs and processes.

Our cybersecurity program utilizes a layered, defense-in-depth strategy to identify and mitigate cybersecurity threats. The company’s information security team is responsible for the day-to-day management of the company’s global information security program, which includes defining policies and procedures to safeguard our information systems and data, conducting vulnerability, threat and third-party information security assessments, information security event management (i.e., responding to ransomware and other cyber-attacks, business continuity and recovery), evaluating external cyber intelligence, supporting industry cybersecurity efforts and working with governmental agencies. The global information security team also develops training for personnel (e.g., employees and contractors) with access to Corteva’s system to support adherence to the company’s policies and procedures, along with increasing awareness of cyber-related risk. The personnel training includes, but is not limited to, mandatory onboarding training, phishing simulations with automated remediation training, table-top incident response exercises, and educational intranet posting and email campaigns.

Our Enterprise Risk Management Committee, which includes the company’s Chief Information Officer (“CIO”) and Chief Information Security Officer (“CISO”), independently assesses and monitors the effectiveness of the company’s cybersecurity risk management programs and strategies. The company’s internal audit function also performs independent reviews and validation of the various programs, including policies and procedures as determined by their annual risk assessment.

The company leverages the U.S. Department of Commerce’s National Institute of Standards and Technology (“NIST”) Cybersecurity Framework (“Framework”) as the foundation of its global information security program. The NIST Framework provides standards, guidelines, and practices for organizations to better manage and reduce cybersecurity risk and is designed to foster risk and cybersecurity management communications amongst both internal and external organizational stakeholders. The company’s information security team works with independent, third-party consultants annually to assess the maturity of the company’s cybersecurity program within the NIST Framework and to develop strategic areas of focus for the company’s programs commensurate with the company’s business objectives.

As part of the company’s global information security program, we leverage both internal and external assessments and partnerships with industry leaders to help approach information security company-wide. Additionally, the company maintains a comprehensive program that defines standards for the planning, sourcing, management, and oversight of third-party relationships and third-party access to its system, facilities, and/or confidential or proprietary data.

Cybersecurity incidents may create risk to the company that may impact its reputation, financial performance, ability to operate safely or at all, and the value of its intellectual property. Like most major corporations, the company is the target of industrial espionage, including cyberattacks, from time to time. The company has determined that these incidents have resulted, and could result in the future, in unauthorized parties gaining access to certain confidential business information. However, to date, Corteva has not experienced any known cybersecurity incidents that have materially affected the company, including the company's results of operations and financial condition, changes in the competitive environment, business operations and strategy. Although management does not believe that Corteva has experienced any material losses to date related to cybersecurity incidents, there can be no assurance that Corteva will not suffer such losses in the future. For more information on potential risk related to cybersecurity incidents, including intellectual property theft and operational disruption, please see “Item 1A – Risk Factors” of this report.

Governance. The company’s Audit Committee and Governance and Compliance Committee provide board oversight of company cybersecurity risks. The Audit Committee conducts a minimum of two cybersecurity program updates per year, including a review of capital spend, budget, and staffing, as well as quarterly reports on cybersecurity threats and key risk indicators related to the company’s progress on risk mitigation activities. The Governance and Compliance Committee, as part of its oversight for the enterprise risk management program company-wide, reviews and ensures that the company’s oversight
24

and governance structure related to company risks, including cybersecurity risks, remains appropriate and that risks are appropriately managed.

The company’s CIO oversees the company’s information technology programs and investments. The company’s CISO reports to the CIO and oversees the company’s information security programs. The company’s CIO has over 30 years of information technology experience, including nine years in various information technology leadership roles. Our CIO holds a bachelor of science and master of science degrees in organizational communications as well as an M.B.A. in information technology. The company’s CISO has over thirty years of experience in information security and is a Certified Information Security Manager® (CISM®), a Certified Data Privacy Solutions Engineer™ (CDPSE®), as well as being Certified in Risk and Information Systems Control® (CRISC®). Our CISO holds a bachelor of science degree in electric engineering as well as an M.B.A. in operations, technology.

Both the CIO and CISO regularly report to the Audit Committee, Board and Governance and Compliance Committee, on the company’s identification, prevention, detection, mitigation and remediation of cybersecurity risks and incidents. In 2023, the Board reviewed the company’s cybersecurity program and maturity assessment, while the Audit Committee provided regular oversight of cybersecurity risks, with cybersecurity discussions and dashboard reviews of key performance indicators and risks at five committee meetings during the course of the year. With respect to specific incidents, the company leverages an incident response framework to elevate and evaluate specific incidents to the CIO and CISO, along with the company’s senior leadership, including the finance and legal functions. In the event of a potentially material cybersecurity incident, the Audit Committee would be immediately notified and briefed.


ITEM 2. PROPERTIES
The company operates out of its headquarters in Indianapolis, Indiana. It also maintains a global business center in Johnston, Iowa, for its seed business. Its manufacturing, processing, marketing and research and development facilities, as well as regional purchasing offices and distribution centers, are located throughout the world. The company has 99 manufacturing sites in the following geographic regions:
Number of Sites
CropSeedTotal
North America1
40 47 
EMEA2
14 22 
Latin America13 21 
Asia Pacific
Total35 64 99 
1.    North America consists of U.S. & Canada.
2.    Europe, Middle East, and Africa ("EMEA").

The company's principal sites include facilities which, in the opinion of management, are suitable and adequate for their use and have sufficient capacity for the company's current needs and expected near-term growth. Properties are primarily owned by the company; however, certain properties are leased. No title examination of the properties has been made for the purpose of this report and certain properties are shared with other tenants under long-term leases.

25


Part I
ITEM 3.  LEGAL PROCEEDINGS

The company is subject to various legal proceedings, including, but not limited to, product liability, intellectual property, antitrust, commercial, property damage, personal injury, environmental and regulatory matters arising out of the normal course of its current businesses or legacy EIDP businesses unrelated to Corteva’s current businesses but allocated to Corteva as part of the Separation of Corteva from DuPont.

Often these proceedings raise complex factual and legal issues, which are subject to risks and uncertainties and which could require significant amounts of senior leadership team’s time. Litigation and other claims, along with regulatory proceedings, against the company could also materially adversely affect its operations, reputation, and/or result in the incurrence of unexpected expenses and liability. Even when the company believes liabilities are not expected to be material or the probability of loss or of an adverse unappealable final judgment is remote, the company may consider settlement of these matters, and may enter into settlement agreements, if it believes settlement is in the best interest of the company, including avoidance of future distraction and litigation defense cost, and its shareholders. Information regarding certain of these matters is set forth below and in Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

Litigation related to Corteva’s current businesses
Federal Trade Commission Investigation
On September 29, 2022, the FTC, along with ten state attorneys general, filed a lawsuit against Corteva and another competitor alleging the parties engaged in unfair methods of competition, unlawful conditioning of payments, unreasonably restrained trade, and have an unlawful monopoly (the “FTC lawsuit”). In December 2022, two additional state attorneys general joined the FTC lawsuit, and another state attorney general filed a separate lawsuit against Corteva and another competitor based on the allegations set forth in the FTC lawsuit. Several proposed private class action lawsuits alleging anticompetitive conduct based on the allegations set forth in the FTC lawsuit were centralized into a multi-district litigation in the U.S. District Court for the Middle District of North Carolina in February 2023. Further information with respect to these proceedings is set forth under “Federal Trade Commission Investigation” in in Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

Lorsban® Lawsuits
As of December 31, 2023, there were pending personal injury and remediation lawsuits filed against the former Dow Agrosciences LLC in California alleging injuries related to exposure to, or contamination by, chlorpyrifos, the active ingredient in Lorsban®, an insecticide used by commercial farms for field fruit, nut and vegetable crops. Corteva ended its production of Lorsban® in 2020. Further information with respect to these proceedings is set forth under “Lorsban® Lawsuits” in Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

Inari Disputes
On September 27, 2023, Corteva filed a lawsuit in Delaware federal court against Inari Agriculture, Inc. and Inari Agriculture. N.V. (collectively “Inari”) asserting claims of Plant Variety Protection infringement, indirect patent infringement, breach of contract, and civil conversion. Corteva’s lawsuit alleges Inari illegally obtained various varieties of seed technologies from a seed depository and illegally transported them abroad for the purpose of performing gene editing on the technologies and then filing a patent for such technologies. In December 2023, Inari filed a motion to dismiss the complaint.

Bayer Disputes
In August 2022, Corteva filed a lawsuit against Bayer CropScience LLP and Monsanto Company (collectively “Bayer”) in federal court in Delaware for alleged infringement of Corteva’s patented AAD-1 herbicide resistance technology used in Enlist® corn. The complaint for this lawsuit was amended to include additional patents that are closely related to this patented technology for soybeans. Corteva seeks to enjoin Bayer from continuing to infringe, as well as appropriate monetary damages. Bayer has filed an answer to the complaint and has asserted various affirmative defenses including invalidity. In August 2023, the court issued a decision adopting Corteva’s claim construction for all five disputed patent terms subject to this litigation.

In December 2023, the Patent Trial and Appeal Board ("PTAB") authorized an Inter Partes Review (“IPR”) proceeding initiated by Bayer to review the patentability of three patents subject to the AAD-1 litigation. Inari is seeking to join the IPR proceeding. An oral hearing will occur before the PTAB in September 2024 with decisions expected by December 2024. Corteva holds numerous additional patents covering its Enlist® traits or Enlist® weed control system. Therefore, the IPR process is not expected to impact our ability to license and protect Enlist E3® traits. Corteva's AAD-1 lawsuit is stayed during pendency of the IPR.

26

Part I
ITEM 3.  LEGAL PROCEEDINGS, continued

In October 2023, the U.S. Patent and Trademark Office granted an ex parte reexamination of the patent for AAD-1 herbicide resistance technology used in Enlist® corn based upon Inari’s petition for review. Inari alleges the AAD-1 patent is not patentably distinct from another Corteva patent for maize technology, and therefore not valid unless Corteva files a terminal disclaimer giving up its patent term adjustment for the AAD-1 technology, which would result in the AAD-1 patent expiring in May 2025.

In August 2022, Bayer filed breach of contract/declaratory judgment lawsuit in Delaware state court against Corteva relating to an agrobacterium cross-license agreement and E3® soybeans. Bayer alleges that Corteva practiced two Bayer patents in developing E3® soybeans, and therefore, is entitled to royalties pursuant to the terms of the cross-license agreement. Further information with respect to these proceedings is set forth under “Bayer Dispute” in Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.

In October 2022, Corteva filed a lawsuit against Bayer in Delaware state court seeking a declaration that, under the terms of Corteva’s licensing agreement and the law, Bayer is not entitled to collect patent royalties on the Roundup Ready® Corn 2 trait after Bayer’s U.S. patent protection expires. In March 2023, Bayer’s motion to dismiss the complaint was denied. Discussions continue between Bayer and Corteva to seek a resolution to these disputes.

Litigation related to legacy EIDP businesses unrelated to Corteva’s current businesses
As discussed below and in Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, certain of the environmental proceedings and litigation allocated to Corteva as part of the Separation from DuPont relate to the legacy EIDP businesses, including their use of PFOA, which, for purposes of this report, means collectively perfluorooctanoic acid and its salts, including the ammonium salt and does not distinguish between the two forms, and PFAS, which means per- and polyfluoroalkyl substances, including PFOA, PFOS (perfluorooctanesulfonic acid), GenX and other perfluorinated chemicals and compounds ("PFCs"). This litigation includes multiple natural resource damage lawsuits across the United States filed by municipalities and alleging PFOA contamination, as well as, lawsuits by four municipalities in the Netherlands filed complaints alleging contamination of land and groundwater resulting from the emission of PFOA and GenX by Corteva, DuPont and Chemours.

In addition to the matters set forth in Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements, on March 25, 2019, the New Jersey Department of Environmental Protection (“NJDEP”) issued a Statewide PFAS Directive to several companies, including Chemours, DuPont, and EIDP. The Directive seeks information relating to the use and environmental release of PFAS and PFAS-replacement chemicals at and from two former EIDP sites in New Jersey, Chambers Works and Parlin, and a funding source for costs related to the NJDEP’s investigation of PFAS issues and PFAS testing and remediation.

On January 22, 2021, Chemours, DuPont, Corteva and EIDP entered into a binding memorandum of understanding containing a settlement to resolve legal disputes related to Chemours' responsibility for litigation and environmental liabilities allocated to it, and to establish a cost sharing arrangement and escrow account to be used to support and manage potential future legacy PFAS liabilities arising out of pre-July 1, 2015 conduct (the “MOU”). See Note 16 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements for further discussion.

Other Environmental Proceedings
The company believes it is remote that the following matters will have a material impact on its financial position, liquidity or results of operations. The matters below involve the potential for $1 million or more in monetary fines and are included per Item 103(3)(c)(iii) of Regulation S-K of the Securities Exchange Act of 1934, as amended.

Related to Corteva’s current businesses

Nebraska Department of Environment and Energy, AltEn Facility
The EPA and the Nebraska Department of Environment and Energy (“NDEE”) are pursuing investigations, response and removal actions, litigation and enforcement action related to an ethanol plant located near Mead, Nebraska and owned and operated by AltEn LLC (“AltEn”). Corteva is one of six seed companies, who were customers of AltEn (collectively, the "Facility Response Group"), participating in the NDEE’s Voluntary Cleanup Program to address certain interim remediation needs at the site. Further information with respect to these proceedings is set forth under “Nebraska Department of Environment and Energy, AltEn Facility” in Note 15 - Commitments and Contingent Liabilities, to the Consolidated Financial Statements.
27

Part I
ITEM 3.  LEGAL PROCEEDINGS, continued

Related to legacy EIDP businesses unrelated to Corteva’s current businesses

Divested Neoprene Facility, La Place, Louisiana - EPA Compliance Inspection
In 2016, the EPA conducted a focused compliance investigation at the Denka Performance Elastomer LLC (“Denka”) neoprene manufacturing facility in La Place, Louisiana. EIDP sold the neoprene business, including this manufacturing facility, to Denka in the fourth quarter of 2015. In the spring of 2017, the EPA, the DOJ, the Louisiana Department of Environmental Quality, EIDP and Denka began discussions relating to the inspection conclusions and allegations of noncompliance arising under the Clean Air Act, including leak detection and repair. These discussions, which include potential settlement options, continue. Under the Separation Agreement, DuPont is defending and indemnifying the company in this matter.

New Jersey Directive Pompton Lakes
On March 27, 2019, the NJDEP issued to Chemours and EIDP a Natural Resource Damages Directive relating to chemical contamination (non-PFAS) at and around EIDP’s former Pompton Lakes facility in New Jersey. The Directive alleges that this contamination has harmed the natural resources of New Jersey. It seeks $125,000 as reimbursement for the cost of preparing a natural resource damages assessment, which the State will use to determine the extent of such damage and the amount it expects to seek to restore the affected natural resources to their pre-damage state.

ITEM 4.  MINE SAFETY DISCLOSURES

Not applicable.


Part II
ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES

Market for Registrant's Common Equity and Related Stockholder Matters
The company's common stock is listed on the New York Stock Exchange, Inc. (symbol: CTVA). The number of record holders of common stock was approximately 66,000 at February 1, 2024.

During 2023 and 2022, the company paid four quarterly dividends on its common stock. See the below table for dividend information for each quarter during 2023 and 2022.

20232022
Fourth Quarter$0.16 $0.15 
Third Quarter0.16 0.15 
Second Quarter0.15 0.14 
First Quarter0.15 0.14 
Total$0.62 $0.58 

See Part III, Item 11. Executive Compensation for information relating to the company’s equity compensation plans.


28

Part II
ITEM 5.  MARKET FOR REGISTRANT'S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES, continued


Issuer Purchases of Equity Securities
The following table summarizes information with respect to the company's purchase of its common stock during the three months ended December 31, 2023:

MonthTotal Number of Shares PurchasedAverage Price Paid per Share
Total Number of Shares Purchased as Part of the Company's Publicly Announced Share Buyback Program1
Approximate Value of Shares that May Yet Be Purchased Under the Program1
(Dollars in millions)
November 20232,150,48346.58 2,150,4831,570 
December 20231,545,477 45.04 1,545,477 1,500 
Fourth quarter 20233,695,960 $45.94 3,695,960 $1,500 
1.On September 13, 2022, Corteva, Inc. announced that its Board of Directors authorized a $2 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date. The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors.

Stock Performance Graph
The following graph illustrates the cumulative total return to Corteva stockholders following the completion of the Separation and beginning as of the closing price of its first NYSE listing date, June 3, 2019. The Chart compares the cumulative total return of Corteva’s common stock with the S&P 500 Stock Index and the S&P 500 Chemicals Index.

SPG.jpg

6/3/201912/31/201912/31/202012/31/202112/31/202212/31/2023
Corteva$100 $120 $161 $198 $249 $205 
S&P 500 Index100 119 141 181 149 188 
S&P 500 Chemicals Index100 112 129 160 139 151 

The chart depicts a hypothetical $100 investment in each of the Corteva common stock, the S&P 500 Index and the S&P 500 Chemicals Index as of the closing price on June 3, 2019 and illustrates the value of each investment over time (assuming the reinvestment of dividends) until December 31, 2023.

ITEM 6.  [RESERVED]
Not applicable.
29

Part II

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

CAUTIONARY STATEMENTS ABOUT FORWARD-LOOKING STATEMENTS

This report contains certain estimates and forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, which are intended to be covered by the safe harbor provisions for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995, and may be identified by their use of words like “plans,” “expects,” “will,” “anticipates,” “believes,” “intends,” “projects,” “estimates,” “outlook,” or other words of similar meaning. All statements that address expectations or projections about the future, including statements about Corteva’s financial results or outlook; strategy for growth; product development; regulatory approvals; market position; capital allocation strategy; liquidity; environmental, social and governance (“ESG”) targets and initiatives; the anticipated benefits of acquisitions, restructuring actions, or cost savings initiatives; and the outcome of contingencies, such as litigation and environmental matters, are forward-looking statements.

Forward-looking statements and other estimates are based on certain assumptions and expectations of future events which may not be accurate or realized. Forward-looking statements and other estimates also involve risks and uncertainties, many of which are beyond Corteva’s control. While the list of factors presented below is considered representative, no such list should be considered to be a complete statement of all potential risks and uncertainties. Unlisted factors may present significant additional obstacles to the realization of forward-looking statements. Consequences of material differences in results as compared with those anticipated in the forward-looking statements could include, among other things, business disruption, operational problems, financial loss, legal liability to third parties and similar risks, any of which could have a material adverse effect on Corteva’s business, results of operations and financial condition. Some of the important factors that could cause Corteva’s actual results to differ materially from those projected in any such forward-looking statements include: (i) failure to obtain or maintain the necessary regulatory approvals for some of Corteva’s products; (ii) failure to successfully develop and commercialize Corteva’s pipeline; (iii) effect of the degree of public understanding and acceptance or perceived public acceptance of Corteva’s biotechnology and other agricultural products; (iv) effect of changes in agricultural and related policies of governments and international organizations; (v) costs of complying with evolving regulatory requirements and the effect of actual or alleged violations of environmental laws or permit requirements; (vi) effect of climate change and unpredictable seasonal and weather factors; (vii) failure to comply with competition and antitrust laws; (viii) effect of competition in Corteva's industry; (ix) competitor’s establishment of an intermediary platform for distribution of Corteva's products; (x) impact of Corteva's dependence on third parties with respect to certain of its raw materials or licenses and commercialization; (xi) effect of volatility in Corteva's input costs; (xii) risk related to geopolitical and military conflict; (xiii) risks related to environmental litigation and the indemnification obligations of legacy EIDP liabilities in connection with the separation of Corteva; (xiv) risks related to Corteva's global operations; (xv) failure to effectively manage acquisitions, divestitures, alliances, restructurings, cost savings initiatives, and other portfolio actions; (xvi) effect of industrial espionage and other disruptions to Corteva’s supply chain, information technology or network systems; (xvii) failure of Corteva’s customers to pay their debts to Corteva, including customer financing programs; (xviii) failure to raise capital through the capital markets or short-term borrowings on terms acceptable to Corteva; (xix) increases in pension and other post-employment benefit plan funding obligations; (xx) capital markets sentiment towards ESG matters; (xxi) risks related to pandemics or epidemics; (xxii) Corteva’s intellectual property rights or defense against intellectual property claims asserted by others; (xxiii) effect of counterfeit products; (xxiv) Corteva’s dependence on intellectual property cross-license agreements; and (xxv) other risks related to the Separation from DowDuPont.

Additionally, there may be other risks and uncertainties that Corteva is unable to currently identify or that Corteva does not currently expect to have a material impact on its business. Where, in any forward-looking statement or other estimate, an expectation or belief as to future results or events is expressed, such expectation or belief is based on the current plans and expectations of Corteva’s management and expressed in good faith and believed to have a reasonable basis, but there can be no assurance that the expectation or belief will result or be achieved or accomplished. Corteva disclaims and does not undertake any obligation to update or revise any forward-looking statement, except as required by applicable law. A detailed discussion of some of the significant risks and uncertainties which may cause results and events to differ materially from such forward-looking statements is included in the section titled “Risk Factors” (Part I, Item 1A of this Form 10-K).






30

Part II

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, continued

Overview
Refer to pages 3 - 4 for a discussion of the DowDuPont Merger, the Internal Reorganizations, and the business separations.

The following is a summary of results from continuing operations for the year ended December 31, 2023:
The company reported net sales of $17,226 million, a decrease of 1 percent versus the year ended December 31, 2022, reflecting a 10 percent decrease in volume and a 1 percent unfavorable impact from currency, partially offset by a 7 percent price increase and a 3 percent favorable portfolio and other impact.
Cost of goods sold ("COGS") totaled $9,920 million, down from $10,436 million for the year ended December 31, 2022, primarily driven by lower volumes, ongoing cost and productivity actions and a decrease in royalty expense, partially offset by higher input costs, which are primarily macro-economic driven.
Restructuring and asset related charges - net were $336 million, a decrease from $363 million for the year ended December 31, 2022. The year ended December 31, 2023 primarily included $217 million related to asset related charges, including non-cash impairment charges of $152 million, and contract termination charges associated with the Crop Protection Operations Strategy Restructuring Program, charges of $72 million of non-cash accelerated prepaid royalty amortization expense related to Roundup Ready 2 Yield® and Roundup Ready 2 Xtend® herbicide tolerance traits and $42 million related to severance and related benefit costs, asset related charges and contract termination charges associated with the 2022 Restructuring Actions.
Income from continuing operations after income taxes was $941 million, as compared to $1,216 million for the year ended December 31, 2022.
Operating EBITDA was $3,381 million, which improved from $3,224 million for the year ended December 31, 2022, primarily driven by price execution and productivity actions, partially offset by lower volumes coupled with cost and currency headwinds. Refer to page 44 for further discussion of the company's Non-GAAP financial measures.

In addition to the financial highlights above, the following events occurred during the year ended December 31, 2023:
The company returned approximately $1.2 billion to shareholders during the year ended December 31, 2023 under its previously announced share repurchase programs and through common stock dividends.
On July 21, 2023, the company's Board of Directors approved a 6.7 percent increase in the quarterly common stock dividend from $0.15 per share to $0.16 per share.

Priorities
The company continues to believe the following priorities will create significant value for its customers and shareholders over the mid-term:
Accelerate performance and growth through a value creation network focused on four key catalysts: (1) portfolio simplification that prioritizes core markets and crops, in which we deliver top tier technology to our customers, (2) a continued move towards royalty neutrality, (3) improve our product mix to focus on differentiation and yield advantage, and (4) operational improvements focused on driving price and productivity.
Increased investment in our industry-leading innovation pipeline focused on delivering even greater value and productivity to growers through more differentiated and sustainably advantaged solutions, which in turn promise to strengthen global food security and help address the impacts of climate change.
Deploy capital with discipline by balancing investment, growth, M&A opportunities and returning cash to shareholders.

31

Part II

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, continued

Analysis of Operations

Acquisitions
On March 1, 2023, Corteva completed its previously announced acquisition of all the outstanding equity interests in Stoller Group Inc. (“Stoller”), one of the largest independent companies in the Biologicals industry, and Quorum Vital Investment, S.L. and its affiliates (“Symborg”), an expert in microbiological technologies. The purchase price for Stoller and Symborg was $1,220 million, inclusive of a working capital adjustment, and $370 million, respectively. These acquisitions supplement the crop protection business with additional biological tools that complement evolving farming practices. See Note 4 - Business Combinations, to the Consolidated Financial Statements, for additional information.

Crop Protection Operations Strategy Restructuring Program
On November 5, 2023, management of the company approved a plan to further optimize its Crop Protection network of manufacturing and external partners (the "Crop Protection Operations Strategy Restructuring Program"). The plan includes the exit of the company’s production activities at its site in Pittsburg, California, as well as ceasing operations in select manufacturing lines at other locations.

The company expects to record aggregate pre-tax restructuring and asset related charges of $410 million to $460 million, comprised of $70 million to $90 million of severance and related benefit costs, $320 million to $340 million of asset-related and impairment charges and $20 million to $30 million of costs related to contract terminations. Reductions in workforce are subject to local regulatory requirements.

Future cash payments related to these charges are anticipated to be $90 million to $120 million, which primarily relate to the payment of severance and related benefits and contract terminations. During the year ended December 31, 2023, the company paid $3 million associated with these charges. The restructuring actions associated with these charges are expected to be substantially complete in 2024.

During the year ended December 31, 2023, the company recorded pre-tax restructuring and asset related charges of $229 million consisting of $217 million and $12 million recognized in restructuring and asset related charges – net and cost of goods sold, respectively, in the company’s Consolidated Statement of Operations, which primarily related to asset-related charges and contract termination charges. Asset-related charges include non-cash impairments charges of $152 million, which were recognized during the year ended December 31, 2023 and consisted of $92 million and $60 million relating to operating lease assets and property, plant and equipment, respectively, associated with the exit of the company’s production activities at its site in Pittsburg, California.

The Crop Protection Operations Strategy Restructuring Program is expected to contribute to the company’s ongoing cost and productivity improvement efforts through achieving an estimated $100 million of savings on a run rate basis by 2025. Future actions by the company or changes in circumstances from current assumptions, including any site disposition gains or losses, may cause actual results and future cash payments to differ. See Note 6 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements for additional information.

2022 Restructuring Actions
In connection with the company’s shift to a global business unit model during 2022, the company assessed its business priorities and operational structure to maximize the customer experience and deliver on growth and earnings potential. As a result of this assessment, the company committed to restructuring actions during the second quarter of 2022, which included the company’s Russia Exit (collectively the “2022 Restructuring Actions”). Through the year ended December 31, 2023, the company recorded pre-tax restructuring and other charges of $373 million inception-to-date under the 2022 Restructuring Actions, consisting of $131 million of severance and related benefit costs, $116 million of asset related charges, $67 million of costs related to contract terminations (including early lease terminations) and $59 million of other charges. The company does not anticipate any additional material charges from the 2022 Restructuring Actions as actions associated with this charge are substantially complete.

Cash payments related to these charges are anticipated to be up to $210 million, of which approximately $150 million has been paid through December 31, 2023, and primarily relate to the payment of severance and related benefits, contract terminations and other charges.

32

Part II

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, continued

The total pre-tax restructuring and other charges recognized through the year ended December 31, 2023 included $53 million associated with the Russia Exit. The Russia Exit pre-tax restructuring charges consisted of $6 million of severance and related benefit costs, $6 million of asset related charges, and $30 million of costs related to contract terminations (including early lease terminations). Other pre-tax charges associated with the Russia Exit were recorded to cost of goods sold and other income (expense) – net in the Consolidated Statement of Operations, relating to inventory write-offs of $3 million and settlement costs of $8 million, respectively.

The 2022 Restructuring Actions are expected to contribute to the company’s ongoing cost and productivity improvement efforts through achieving an estimated $210 million to $220 million of savings on a run rate basis by 2025. See Note 6 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements for additional information.

Share Buyback Plan
On September 13, 2022, Corteva, Inc. announced that its Board of Directors authorized a $2 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2022 Share Buyback Plan"). The timing, price and volume of purchases will be based on market conditions, relevant securities laws and other factors. In connection with the 2022 Share Buyback Plan, the company repurchased and retired 10,026,000 shares in the open market for a cost (excluding excise taxes) of $500 million during the year ended December 31, 2023.

On August 5, 2021, Corteva, Inc. announced that its Board of Directors authorized a $1.5 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2021 Share Buyback Plan"). The company completed the 2021 Share Buyback Plan during the first quarter of 2023 and repurchased and retired 4,098,000, 17,425,000 and 5,572,000 shares in the open market for a total cost of $250 million, $1 billion, and $250 million during the years ended December 31, 2023, 2022 and 2021, respectively.

On June 26, 2019, Corteva, Inc. announced that its Board of Directors authorized a $1 billion share repurchase program to purchase Corteva, Inc.'s common stock, par value $0.01 per share, without an expiration date ("2019 Share Buyback Plan"). The company completed the 2019 Share Buyback Plan during the third quarter of 2021 and repurchased and retired 24,705,000 shares between the years ended December 31, 2019 and 2021 in the open market.

2021 Restructuring Actions
During the first quarter of 2021, Corteva approved restructuring actions designed to right-size and optimize footprint and organizational structure according to the business needs in each region with the focus on driving continued cost improvement and productivity. Through the year ended December 31, 2023, the company recorded net pre-tax restructuring charges of $167 million inception-to-date under the 2021 Restructuring Actions, consisting of $70 million of severance and related benefit costs, $45 million of asset related charges, $12 million of asset retirement obligations and $40 million of costs related to contract terminations (contract terminations includes early lease terminations). Actions associated with the 2021 Restructuring Actions were substantially complete by the end of 2021. The company expected the 2021 Restructuring Actions to contribute to the company’s ongoing cost and productivity improvement efforts and achieve an estimated $70 million of savings on a run rate basis by 2023, which was achieved. See Note 6 - Restructuring and Asset Related Charges - Net, to the Consolidated Financial Statements, for additional information.

Results of Operations

Net Sales
For the Year Ended December 31,
(In millions) 202320222021
Net Sales$17,226 $17,455 $15,655 
2023 versus 2022
Net sales were $17,226 million for the year ended December 31, 2023, compared to $17,455 million for the year ended December 31, 2022. The decrease was primarily driven by a 10 percent decrease in volume versus the prior year and a 1 percent unfavorable impact from currency, partially offset by a 7 percent increase in price and a 3 percent favorable portfolio and other impact. Volume declines were driven by strategic product exits, crop protection channel inventory destocking, delayed farmer purchases, lower corn planted area in EMEA, reduced summer corn planted area and lower expected Safrinha corn planted area in Brazil, and the Russia Exit, partially offset by increased corn acres in North America. The unfavorable currency impacts
33

Part II

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, continued

were led by the Turkish Lira, Canadian Dollar and Chinese Renminbi. Price gains were driven by continued execution on the company's price for value strategy, strong demand for new technology and strong execution in response to cost inflation led by EMEA, partially offset by challenging market dynamics in Latin America and North America. The portfolio and other impact was driven by the biologicals acquisitions and the sale of seeds already under production in Russia when the decision to exit the country was made and that the company was contractually required to purchase.

2022 versus 2021
Net sales were $17,455 million for the year ended December 31, 2022, compared to $15,655 million for the year ended December 31, 2021. The increase was primarily driven by a 10 percent increase in price and a 5 percent increase in volume versus the prior year period, partially offset by a 3 percent unfavorable currency impact and 1 percent unfavorable portfolio impact. Price gains were driven by the continued execution on the company's price for value strategy with strong execution across all regions in response to cost inflation, and recovery of higher input costs. The increase in volume was driven by continued penetration of new products and gains in all regions, partially offset by reduced corn acres in North America and supply constraints in North America canola. The unfavorable currency impacts were led by the Turkish Lira and the Euro, partially offset by the Brazilian Real. The portfolio impact was driven by a divestiture in Asia Pacific.
 For the Year Ended December 31,
(In millions) 202320222021
Net Sales% of Net SalesNet Sales% of Net SalesNet Sales% of Net Sales
Worldwide$17,226 100 %$17,455 100 %$15,655 100 %
North America
8,590 50 %8,294 48 %7,536 48 %
EMEA
3,367 19 %3,256 19 %3,123 20 %
Latin America3,906 23 %4,445 25 %3,545 23 %
Asia Pacific1,363 %1,460 %1,451 %

Year Ended December 31, 2023 vs. 2022Percent Change Due To:
Net Sales ChangePrice &Portfolio /
(in millions)$%Product MixVolumeCurrencyOther
North America$296 %%(2)%— %— %
EMEA111 %19 %(11)%(8)%%
Latin America(539)(12)%%(25)%%%
Asia Pacific(97)(7)%%(9)%(5)%— %
Total$(229)(1)%%(10)%(1)%%
Year Ended December 31, 2022 vs. 2021Percent Change Due To:
Net Sales ChangePrice &Portfolio /
(in millions)$%Product MixVolumeCurrencyOther
North America$758 10 %%%— %— %
EMEA133 %10 %%(14)%— %
Latin America900 25 %16 %%%— %
Asia Pacific%%%(6)%(2)%
Total$1,800 11 %10 %%(3)%(1)%
34

Part II

ITEM 7.  MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS, continued


COGS
For the Year Ended December 31,
(In millions) 202320222021
COGS$9,920 $10,436 $9,220 
2023 versus 2022
COGS was $9,920 million (58 percent of net sales) for the year ended December 31, 2023 compared to $10,436 million (60 percent of net sales) for the year ended December 31, 2022. The decrease was primarily driven by lower volumes, ongoing cost and productivity actions and a decrease in royalty expense, partially offset by higher input costs, which are primarily macro-economic driven. The macro-economic driven trends are due to inflationary pressures impacting raw material inputs, which are expected to improve in 2024.

2022 versus 2021
COGS was $10,436 million (60 percent of net sales) for the year ended December 31, 2022 compared to $9,220 million (59 percent of net sales) for the year ended December 31, 2021. The increase was primarily driven by increased volumes in crop protection, and higher input costs, freight and logistics, which were primarily market-driven. The increases were partially offset by ongoing cost and productivity actions and a favorable impact from currency.

Research and Development Expense ("R&D")
For the Year End